Combination therapies and patient stratification with bispecific Anti-EGFR / c-met antibodies

JP2024153659A5Inactive Publication Date: 2024-11-14JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024108371
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-04
Filing Date
2024-07-04
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Relapse or resistance to existing treatments is common in cancers expressing EGFR or c-Met, necessitating a combination of therapeutic agents and patient stratification biomarkers for more effective treatments.

Method used

A method involving bispecific anti-EGFR/c-Met antibodies is used in combination with agents that enhance macrophage activity, administered based on macrophage or monocyte levels in biological samples, to treat and diagnose cancers expressing EGFR or c-Met.

Benefits of technology

Enhances treatment efficacy by predicting patient response and improving macrophage interactions, leading to better tumor killing and overall therapeutic outcomes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a pharmaceutical composition for use in a method of treating a subject having EGFR, c-Met, or EGFR or c-Met expressing cancer.SOLUTION: The present invention provides a pharmaceutical composition for use in a method of treating a subject. The pharmaceutical composition comprises an isolated bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody. The method comprises administering a therapeutically effective amount of the isolated bispecific anti-EGFR / c-Met antibody to the subject in combination with an agent that enhances macrophage activity in the subject.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to combination therapy with bispecific anti-EGFR / c-Met antibodies and patient stratification. do.

[0002] (Sequence Listing) This application contains a sequence listing submitted via EFS-Web, the entire contents of which are hereby incorporated by reference. The ASCII text file was created on February 13, 2020. The file is named JBI6051WOPCT1ST25.txt and is 19 kilobytes in size. It is a thread. [Background technology]

[0003] The individual roles of both EGFR and c-Met in cancer are well established. These targets are attractive for combination therapy. Signals through survival and anti-apoptotic pathways (ERK and AKT); thus Inhibiting this pair of pathways together limits the possibility of activating the compensatory pathway, thereby This may improve overall efficacy. Summary of the Invention [Problem to be solved by the invention]

[0004] Relapse or resistance to existing treatments is common. Improved therapeutic agents or therapeutic options are being developed to develop more effective treatments for diseases such as Met-positive cancer. There is a need for a combination of therapeutic agents and patient stratification biomarkers. [Means for solving the problem]

[0005] The present disclosure provides a method of treating a subject having an EGFR or c-Met expressing cancer, comprising administering to said subject A therapeutically effective amount of isolated macrophages in combination with an agent that enhances macrophage activity in elephants. Bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody The method includes administering to a subject a

[0006] The present disclosure also provides methods for treating EGFR-related disorders that respond to treatment with bispecific anti-EGFR / c-Met antibodies. or a method for diagnosing and treating a subject having a c-Met-expressing cancer, comprising: Providing a sample and measuring macrophage or monocyte levels from the biological sample. When the level of macrophages or monocytes from the biological sample is greater than the threshold, the subject is diagnosed with a bispecific EGFR or c-Met expressing cancers that respond to treatment with heterologous anti-EGFR / c-Met antibodies and diagnosed as responding to treatment with anti-EGFR / c-Met antibody. The bispecific anti-EGFR / c-Met antibody is administered or offered for administration to the subject. and providing a method for detecting the presence of a fluorine-containing compound.

[0007] The present disclosure also relates to a subject suspected of having or having an EGFR or c-Met expressing cancer. A method of treating a subject with a bispecific anti-EGFR / c-Met antibody, comprising: Determining that the subject has a high macrophage or monocyte level and determining that the subject has a macrophage or monocyte level higher than a threshold value Subjects who were determined to have phage or monocyte levels were administered the bispecific anti-EGFR / c-Met administering or providing for administration the antibody.

[0008] The present disclosure also provides methods for treating EGFR or c-Met disorders using bispecific anti-EGFR / c-Met antibodies. The present invention relates to a method for predicting the response of a subject having a c-Met-expressing cancer, the method comprising: providing a biological sample; measuring macrophage or monocyte levels from the biological sample; A subject is a responder when the level of macrophages or monocytes from the body sample is greater than a threshold value. and predicting that the

[0009] The present disclosure also provides methods for treating EGFR-related disorders that respond to treatment with bispecific anti-EGFR / c-Met antibodies. or a method of treating a subject having a c-Met-expressing cancer, comprising providing a biological sample from the subject. measuring a level of macrophages or monocytes from the biological sample; When the macrophage or monocyte levels from the sample are above a threshold, the subject is treated with bispecific anti-EGF and treating with a FR / c-Met antibody.

[0010] The present disclosure also provides a method for treating a subject with an EGFR or c-Met expressing cancer, comprising administering to the subject a bispecific anti-EGFR and determining whether the subject responds to treatment with a c-Met antibody, and whether to treat the subject. A method for isolating macrophages from a subject, the method comprising providing a biological sample from a subject and extracting macrophages from the biological sample. and measuring macrophage or monocyte levels from a biological sample. When the level is higher than the threshold, the subject with EGFR or c-Met expressing cancer is or by detecting a specific antibody from a biological sample. When the macrophage or monocyte level is below the threshold, EGFR or c-Met -expressing cancers do not respond to treatment with bispecific anti-EGFR / c-Met antibodies and responding to treatment with a bispecific anti-EGFR / c-Met antibody. or administering a bispecific anti-EGFR / c-Met antibody to the subject. Bispecific anti-EGFR / c-Met antibody therapy in subjects diagnosed as non-responsive to treatment and refraining from administering the c-Met antibody. [Brief description of the drawings]

[0011] [Figure 1] Figure 2 shows JNJ-372-mediated inhibition of proliferation of NucLight Red-labeled NCI-H1975 cells in the presence of PBMC at the indicated JNJ-372 concentrations for up to 120 hours in culture, as measured using NucLight Red cells / mm2. [Diagram 2] Shown is the effect of JNJ-372 mediated on the proliferation of NucLight Red labeled NCI-H1975 cells in the absence of PBMCs at the indicated JNJ-372 concentrations up to 120 hours in culture, as measured using NucLight Red cells / mm2. [Diagram 3] Figure 1 shows JNJ-372, JNJ-372.IgG2 Sigma, JNJ-372.NF, or isotype control mediated inhibition of proliferation of NucLight Red labeled NCI-H1975 cells in the presence of PBMC. Proliferation was not inhibited in the absence of PBMC, by isotype control, or by Fc effector silent JNJ-372.IgG2 Sigma. JNJ-372.NF cultured in the presence of PBMC partially inhibited proliferation. Iso: isotype control; IgG2s: JNJ-372.IgG2 Sigma; EGFRxMet NF: JNJ-372.NF. [Figure 4]Figure 1 shows JNJ-372, JNJ-372.IgG2 Sigma, JNJ-372.NF, or isotype control mediated apoptosis of NucLight Red labeled NCI-H1975 cells in the presence of PBMCs after 48 hours of culture. Apoptosis was not induced in the absence of PBMCs, by isotype control, or by Fc effector silent JNJ372.IgG2 Sigma. JNJ-372.NF cultured in the presence of PBMCs partially mediated apoptosis. Iso: isotype control; IgG2s: JNJ-372.IgG2 Sigma; EGFRxMet NF: JNJ-372.NF. [Diagram 5] Images from capillary-based electrophoresis (Simple Western with PeggySue) are shown showing EGFR, c-Met, and pEGFR proteins in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured with or without PBMCs for 4, 24, 48, or 72 hours, as indicated. The presence of PBMCs enhanced JNJ-372-mediated downregulation of EGFR and c-Met proteins and inhibition of pEGFR. [Figure 6] The relative amount of EGFR (normalized to actin, a loading control) is shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured in the presence or absence of PBMCs for 4, 24, 48, or 72 hours, as indicated. The presence of PBMCs enhanced JNJ-372-mediated downregulation of EGFR. [Figure 7] The relative amounts of pEGFR (pY1173) (normalized to actin, a loading control) are shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured with or without PBMCs for 4, 24, 48, or 72 hours, as indicated. The presence of PBMCs enhanced JNJ-372-mediated downregulation of pEGFR. [Figure 8]The relative amounts of c-Met (normalized to actin, a loading control) are shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured in the presence or absence of PBMCs for 4, 24, 48, or 72 hours, as indicated. The presence of PBMCs enhanced JNJ-372-mediated downregulation of c-Met. [Figure 9] Images from capillary-based electrophoresis (Simple Western with PeggySue) are shown showing EGFR, c-Met, and pEGFR proteins in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured for 48 hours in the presence or absence of PBMCs from seven different donors, as indicated. [Figure 10] The relative amount of EGFR (normalized to actin, a loading control) is shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured for 48 hours in the presence or absence of PBMCs from seven different donors, as indicated. [Figure 11] The relative amounts of pEGFR(pY1173) (normalized to actin, a loading control) are shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured for 48 hours in the presence or absence of PBMCs from seven different donors, as indicated. [Figure 12] The relative amounts of c-Met (normalized to actin, a loading control) are shown in NCI-H1975 samples treated with isotype control or JNJ-372 and cultured for 48 hours in the presence or absence of PBMCs from seven different donors, as indicated. [Figure 13] Correlation between % monocytes in each donor's PBMC sample and % change in EGFR inhibition by JNJ-372 in the presence of PBMCs (relative fold change vs. no PBMCs) as measured by the amount of EGFR protein in NCI-H1975 cells (normalized to actin, a loading control) is shown. [Figure 14]Correlation between % monocytes in each donor's PBMC sample and % change in pEGFR Y1173 inhibition by JNJ-372 in the presence of PBMCs (relative fold change vs. no PBMCs) as measured by the amount of pEGFR protein in NCI-H1975 cells (normalized to actin, a loading control). [Figure 15] Correlation between % monocytes in each donor's PBMC sample and % change in c-Met inhibition by JNJ-372 in the presence of PBMCs (relative fold change vs. no PBMCs) as measured by the amount of c-Met protein in NCI-H1975 cells (normalized to actin, a loading control) is shown. [Figure 16] Images are shown from capillary-based electrophoresis (Simple Western with PeggySue) detecting EGFR, c-Met, and pEGFR protein levels in NCI-H1975 cells treated with JNJ-372 or isotype control and cultured for 48 hours in the presence or absence of NK cell-depleted or monocyte (mono)-depleted PBMCs from one donor, as indicated. [Figure 17] The relative amount of EGFR (normalized to actin, a loading control) is shown in NCI-H1975 cells treated with JNJ-372 or isotype control and cultured for 48 hours in the presence or absence of NK cell-depleted or monocyte (mono)-depleted PBMCs from one donor, as indicated. [Figure 18] Relative amounts of pEGFR(pY1173) (normalized to actin, a loading control) are shown in NCI-H1975 treated with JNJ-372 or isotype control and cultured for 48 hours in the presence or absence of NK cell-depleted or monocyte (mono)-depleted PBMCs from one donor, as indicated. [Figure 19] Relative amounts of c-Met (normalized to actin, a loading control) are shown in NCI-H1975 treated with JNJ-372 or isotype control and cultured for 48 hours in the presence or absence of NK cell-depleted or monocyte (mono)-depleted PBMCs from one donor, as indicated. [Figure 20] Shown are images from capillary-based electrophoresis (Simple Western with PeggySue) detecting EGFR, c-Met, and pEGFR protein levels in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 Sigma, or isotype control for 48 hours in the presence or absence of PBMCs, isolated NK cells, isolated monocytes, MCSF-differentiated M1 macrophages, or GMCSF-differentiated M1 macrophages from the same donor, as indicated. [Figure 21] Relative amounts of EGFR (normalized to actin, a loading control) are shown in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 sigma, or isotype control for 48 hours in the presence or absence of PBMCs, monocytes, MCSF-differentiated M1 macrophages, or GMCSF-differentiated M1 macrophages isolated from the same donor, as indicated. [Figure 22] Relative amounts of pEGFR(pY1173) (normalized to actin, a loading control) are shown in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 Sigma, or isotype control for 48 hours in the presence or absence of PBMCs, monocytes, MCSF-differentiated M1 macrophages, or GMCSF-differentiated M1 macrophages isolated from the same donor, as indicated. [Diagram 23] Relative amounts of c-Met (normalized to actin, a loading control) are shown in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 sigma, or isotype control for 48 hours in the presence or absence of PBMCs, monocytes, MCSF-differentiated M1 macrophages, or GMCSF-differentiated M1 macrophages isolated from the same donor, as indicated. [Figure 24]Shown are images from capillary-based electrophoresis (Simple Western with PeggySue) detecting EGFR, c-Met, and pEGFR protein levels in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 Sigma, or isotype control and cultured in the presence of M1 macrophages (M1) or M2a macrophages (M2a), as indicated. Iso: isotype control, 372: JNJ-372, IgG2 Sigma: JNJ-372.IgG2 Sigma. [Diagram 25] Shown are images from capillary-based electrophoresis (Simple Western with PeggySue) detecting EGFR, c-Met, and pEGFR protein levels in NCI-H1975 cells treated with JNJ-372, JNJ-372.IgG2 Sigma, or isotype control and cultured in the presence or absence of M2c macrophages (M2c) for 48 hours, as indicated. Iso: isotype control, 372: JNJ-372, IgG2 Sigma: JNJ-372.IgG2 Sigma. [Figure 26] Images are shown from capillary-based electrophoresis (Simple Western with PeggySue) detecting EGFR, c-Met, pEGFR, and pMet protein levels in SNU-5 cells treated with JNJ-372 or isotype control and cultured in the presence or absence of PBMCs, as indicated. [Figure 27] The relative amount of EGFR (normalized to actin, a loading control) is shown in SNU-5 cells treated with JNJ-372 or isotype control and cultured in the presence or absence of PBMCs for 48 hours, as indicated. [Figure 28] The relative amount of pEGFR(pY1173) (normalized to actin, a loading control) is shown in SNU-5 cells treated with JNJ-372 or isotype control and cultured in the presence or absence of PBMCs for 48 hours, as indicated. [Figure 29]The relative amounts of c-Met (normalized to actin, a loading control) are shown in SNU-5 cell culture samples cultured for 48 hours in the presence or absence of JNJ-372, isotype control, or PBMC, as indicated. [Diagram 30] The relative amounts of pMet (pY1234 / 1235) (normalized to actin, a loading control) are shown in SNU-5 cells treated with JNJ-372 or isotype control and cultured for 48 hours in the presence or absence of PBMCs, as indicated. [Diagram 31] Tumor volumes of subcutaneously injected H1975 cell line xenograft tumors treated with 10 mg / kg isotype control (n=8), JNJ-372 (n=8), or JNJ-372.IgG2 sigma (IgG2σ in figure) (n=8) BIW for 3 weeks are shown. On day 24, TGI% was calculated. [Diagram 32] Tumor volumes of subcutaneously injected SNU5 cell line xenograft tumors treated with vehicle (PBS) (n=8), 5 mg / kg JNJ-372 (n=8), or JNJ-372.IgG2 Sigma (IgG2σ in figure) (n=8) BIW for 3 weeks are shown. TGI% was calculated on day 34. All data are expressed as mean ± SEM within each treatment group. [Diagram 33] BATDA-loaded H1975 cells treated with JNJ-372 for 2 hours in the presence of PBMCs, NK cells, or monocytes isolated from the same donor at E:T ratios of 25:1, 5:1, and 5:1, respectively, and ADCC lysis measured by europium release are shown. [Diagram 34] Figure 1 shows the number of tumor-associated macrophages using multicolor flow cytometry analysis of H1975 tumor samples isolated 24 hours after two doses of 10 mg / kg isotype, JNJ-372, or JNJ-372.IgG2 sigma treatment (n=5 mice / treatment) to determine the percentage of macrophages (CD45+CD11b+Ly6G-Ly6C-F4 / 80+) within the tumor after depletion with anti-mouse CSF1R antibody. [Diagram 35]Figure 1 shows tumor volumes of subcutaneously injected H1975 cell line xenograft tumors treated with 10mg / kg JNJ-372, JNJ-372.IgG2 sigma, or isotype (n=8 mice per treatment group) BIW for 3 weeks in combination with anti-mouse CSF1R or its isotype control 3 times a week to deplete macrophages. TGI% was calculated on day 21, ****, p value <0.0001 was calculated by 2-way ANOVA on day 17 (when all groups had all mice in the study). [Diagram 36] Bar graphs depicting the relative fold change of the indicated chemokines and cytokines produced by H1975 cells following 4 hour treatment with JNJ-372 or JNJ-372.IgG2 Sigma in the presence of PBMCs versus isotype. [Figure 37] Bar graphs depicting the relative fold change of the indicated chemokines and cytokines produced by H1975 cells following 72 hour treatment with JNJ-372 or JNJ-372.IgG2 Sigma in the presence of PBMCs versus isotype. [Figure 38] Relative fold change in MCP-1 production in H1975 cells treated with the indicated dose ranges of JNJ-372 versus untreated for 4 h in the presence of PBMCs (E:T=10:1) (first five bars from the left), NK cells (sixth to tenth bars from the left), or monocytes (first five bars from the right) at an effector:target ratio of 5:1 (E:T=5:1). [Figure 39] 1 shows dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MCP-3 levels upon treatment of H1975 cells with JNJ-372 in the presence of PBMCs, NK cells, or monocytes. The dotted grey line indicates the value for the untreated control. [Diagram 40]Relative fold change in IL1-RA (ILRA indicated in figure) production in H1975 cells treated with the indicated dose ranges of JNJ-372 versus untreated for 4 h in the presence of PBMCs (E:T=10:1) (first five bars from the left), NK cells (6th to 10th bars from the left), or monocytes (first five bars from the right) at an effector:target ratio of 5:1 (E:T=5:1). [Diagram 41] 1 shows dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MIP-1β levels upon treatment of H1975 cells with JNJ-372 in the presence of PBMCs, NK cells, or monocytes. The dotted grey line indicates the value for the untreated control. [Diagram 42] Dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MIP-1β levels upon treatment of H1975 cells with JNJ-372, JNJ-372.IgG2 Sigma (IgG2σ in the figure), or isotype control in the presence of M1 macrophages (M1 macs). The grey dotted line indicates the value for the untreated control. [Diagram 43] Dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MIP-1β levels upon treatment of H1975 cells with JNJ-372, JNJ-372.IgG2 sigma (IgG2σ in the figure), or isotype control in the presence of M2 macrophages (M2 macs). The grey dotted line indicates the value for the untreated control. [Diagram 44] Dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MIP-1α levels upon treatment of H1975 cells with JNJ-372, JNJ-372.IgG2 Sigma (IgG2σ in the figure), or isotype control in the presence of M1 macrophages (M1 macs). The grey dotted line indicates the value for the untreated control. [Diagram 45]Dose-response curves from an MSD-based cytokine analysis measuring the fold change (compared to untreated control) in MIP-1α levels upon treatment of H1975 cells with JNJ-372, JNJ-372.IgG2 Sigma (IgG2σ in the figure), or isotype control in the presence of M2 macrophages (M2 macs). The grey dotted line indicates the value for the untreated control. [Figure 46] Dose-response curves from a flow cytometry-based trogocytosis assay measuring % AF488 labeling in CD11b positive M1 macrophages upon opsonization of H1975 cells for 3 hours with labeled isotype, JNJ-372, or JNJ-372.IgG2 sigma (IgG2σ in the figure). Treatment with JNJ-372, but not isotype or IgG2, induced dose-dependent trogocytosis by M1 macrophages. [Figure 47] Dose-response curves from a flow cytometry-based trogocytosis assay measuring % AF488 labeling in CD11b positive M2 macrophages upon opsonization of H1975 cells with labeled isotype, JNJ-372, or JNJ-372.IgG2 sigma (IgG2σ in the figure) for 3 hours. Treatment with JNJ-372, but not isotype or IgG2, induced dose-dependent trogocytosis by M2 macrophages. [Figure 48]Representative images from high-content confocal microscopy depict trogocytosis of M2 macrophages labeled with FITC-CD11b (labels macrophage plasma membrane) and Hoechst (labels nuclei) in coculture (E:T ratio = 5:1) with H1975 NucLight Red cells opsonized with AF647-labeled JNJ-372 (top panel) or JNJ-372.IgG2 Sigma (bottom panel) after 11 minutes (min) or 44 min of opsonization. White arrows indicate trogocytosis events as measured by transfer of AF647-labeled JNJ-372 antibody from target cells to M2 macrophages. Trogocytosis was not evident with JNJ-372.IgG2. Scale bar = 20 μm. M: macrophages; T: H1975 cells. [Figure 49] (Legend for WOPCT1 greyscale) Representative images from high content confocal microscopy showing trogocytosis of M2 macrophages labeled with FITC-CD11b (labels macrophage plasma membrane) and Hoechst (labels nuclei) in coculture (E:T ratio = 5:1) with H1975 NucLight Red cells opsonized with AF647-labeled JNJ-372 (top panel) or JNJ-372.IgG2 Sigma (bottom panel) after 77 or 110 min of opsonization. White arrows indicate trogocytosis events as measured by transfer of AF647-labeled JNJ-372 antibody from target cells to M2 macrophages. Trogocytosis was not evident with JNJ-372.IgG2. Scale bar = 20 μm. M: macrophages; T: H1975 cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] definition All of the above, including but not limited to, the patents and patent applications cited herein. publications are incorporated herein by reference as if fully set forth.

[0013] The terminology used in this specification is used only to describe particular embodiments and is not intended to be limiting. It should be understood that no intent to imply this is intended to be a substitute for the teachings of the present invention. All technical and scientific terms used herein are commonly understood by one of ordinary skill in the art to which this invention belongs. has the same meaning as previously understood.

[0014] Any methods and materials similar or equivalent to those described herein may be used in the testing of the present invention. Exemplary materials and methods can be used to perform the method described herein. In describing and claiming the present invention, the following terminology is used.

[0015] Where a list is presented, unless otherwise specified, each individual element of the list and its sublists are treated as part of the It should be understood that every combination of the above statements is a separate embodiment. A list of embodiments presented as "A," "B," "C," or "D" is intended to include embodiments "A," "B," "C," "D," "E," "F," "G," "H," "I," "IJ ... "A or B," "A or C," "B or C," or "A, B, or C" shall be interpreted as including It should be.

[0016] As used in this specification and the appended claims, the singular forms "a," "an," " and "the" includes plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a reference to a group of two or more cells. This includes combinations and the like.

[0017] The term "and / or" connecting multiple listed elements refers to both the individual and combined For example, if two elements are combined in "and / or" Thus, when connected, the first option is that the first element is applicable without the second element. The second option indicates that the second element is applicable without the first element. The third option indicates that the first and second elements are applicable together. Any one of the alternatives is encompassed within the meaning and therefore as used herein. It is understood that the term "and / or" is used interchangeably. It is understood that the use of "and / or" is also included in the meaning and therefore meets the requirements of the term "and / or." will be done.

[0018] The transitional phrases "comprising" and "consisting essentially of" "To be specific of" and "consisting of" are terms that are generally accepted in patent language. The term "comprises" is intended to imply the meaning given to the term "comprising" or "including" in the following sense: "comprises," "contains," or "features" is synonymous with "comprises," "contains," or "features" and is inclusive or non-exclusive. It is intended to be limiting and not to exclude other unrecited elements or method steps. and (ii) "consisting of" is specified in the claim. and (iii) "consisting essentially of." The patent requires that the specified materials or steps, as well as the "basic and novel features" of the claimed invention, The phrase "comprises" a portion of the claims that does not substantially affect the An embodiment described in terms of "comprising" (or its equivalents) also includes As an embodiment, the terms "consisting of" and "consisting essentially of" are provided separately. Provide.

[0019] "Concurrent administration," "administered with," "administered in combination with," "in combination with," etc. The present invention encompasses administration of a selected therapeutic agent or drug to a single patient, where the therapeutic agent or drug is the same or different from the selected therapeutic agent or drug. or by different routes of administration or at the same or different times. It is intended to

[0020] "Isolated" means substantially free from other components of the system in which a molecule is produced, such as a recombinant cell. A homogenous population of quantitatively isolated and / or purified molecules (e.g., synthetic polynucleotides, poly peptide, vector, or virus) and subjected to at least one purification or isolation step. "Isolated" refers to a protein that is substantially free of other cellular material and / or chemicals. It refers to molecules that are essentially free of %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 Molecules isolated to 95%, 96%, 97%, 98%, 99% or 100% purity Includes:

[0021] "Treating," "treating," or "treatment" of a disease or disorder, such as cancer, includes the following: Achieving one or more of the following: Reducing the severity and / or duration of the disorder inhibiting the worsening of symptoms characteristic of the disorder being treated; in subjects who previously had the disorder; limiting or preventing the recurrence of a disorder in a subject who was previously symptomatic for the disorder limit or prevent the recurrence of symptoms in

[0022] "Preventing," "preventing," "prevention," or "prophylactic treatment" of a disease or disorder refers to This means preventing the development of disorders in elephants.

[0023] "Diagnose" or "diagnosis" refers to determining whether a subject is afflicted with a given disease or condition. or whether a person may develop a given disease or condition in the future, or whether a person has a previously diagnosed disease or condition or whether a patient is likely to respond to treatment for a condition, i.e., whether a patient is likely to respond to treatment for a condition. It refers to a method of stratifying a patient population for the likelihood of responding to a diagnostic test. General guidance about the disease being treated, or that a subject is likely to respond to a particular treatment The test is performed by a physician based on other criteria indicating

[0024] "Respond," "responsiveness," or "likely to respond" refers to detectable or undetectable Any kind of improvement or positive response, whether possible or not, e.g., one or more alleviation or amelioration of symptoms, reduction in the extent of disease, or a stabilized (i.e., not worsening) disease state , prevention of the spread of disease, delay or slowing of disease progression, amelioration or alleviation of the disease state, and remission (part It refers to a system of operations (whether partial or holistic).

[0025] "Newly diagnosed" means a cancer that has been diagnosed as EGFR- or c-Met-expressing, but The term refers to subjects who have not yet received treatment for primary myeloma.

[0026] A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount will depend on factors such as the individual's condition, age, sex, and weight, as well as the individual's The efficacy of one or a combination of therapeutic agents varies depending on the ability of the therapeutic agent to elicit the desired response. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, , improved health of the patient.

[0027] "Refractory" refers to a disease that does not respond to treatment. Refractory diseases are those that are difficult to treat before or at the start of treatment. The disease may be resistant to treatment or a refractory disease may become resistant during treatment.

[0028] "Recurrent" means a recurrence of a disease or signs and symptoms of a disease after a period of improvement following prior treatment with a therapeutic agent. It means to restart.

[0029] A "subject" includes any human or non-human animal. A "non-human animal" includes all vertebrate animals, For example, mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows The terms "subject" and "patient" are used interchangeably herein. Used interchangeably.

[0030] "About" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art. This means that the value is subject to the limitations of the way in which it is measured or determined, i.e. the measurement system. To some extent, the examples or paragraphs may be used in the context of a particular assay, result, or embodiment. Unless expressly stated otherwise elsewhere in the specification, "about" is intended to be within the scope of the practice of the art. This means that the difference is within one standard deviation or 5% of the range, whichever is greater. do.

[0031] Cancer is a type of cancer that grows in an uncontrolled manner and can sometimes spread to other areas of the patient's body. It refers to an abnormal growth of cells that tends to migrate (spread).

[0032] "EGFR- or c-Met-expressing cancer" refers to cancers in which there is detectable expression of EGFR or c-Met. It refers to cancers that have the onset of EGFR or c-Met mutations or amplifications. EGFR or c-Met expression, amplification, and mutation status were determined by sequencing, fluorescence in situ Hybridization, immunohistochemistry, flow cytometry, or western Detection can be achieved using known methods such as blotting.

[0033] "Epidermal growth factor receptor" or "EGFR" is GenBank Accession No. NP Human EGFR (HER1 or Erb) having the amino acid sequence shown in Also known as B1 (Ullrich et al., Nature 309:4 18-425, 1984), as well as its naturally occurring variants.

[0034] "Hepatocyte growth factor receptor" or "c-Met" as used herein refers to GenB ank accession number NP_001120972 This term refers to human c-Met, as well as naturally occurring variants thereof.

[0035] “Bispecific anti-EGFR / c-Met antibody” or “bispecific EGFR / c-Met anti-antibody” The antibody comprises a first domain that specifically binds to EGFR and a second domain that specifically binds to c-Met. This refers to a bispecific antibody that has a second domain that specifically binds to EGFR and c-Met. The domains that bind are typically VH / VL pairs, such as bispecific anti-EGFR / c-Met The antibody is monovalent for binding to EGFR and c-Met.

[0036] "Specific binding" or "specifically binds" or "specific binding" or "binding" " refers to an antibody that binds to an antigen or an epitope within an antigen with greater affinity than to other antigens. Typically, an antibody binds to a cell of about 5×10 -8M or less, for example, about 1×10 -9 M or less, approximately 1×10 -10 M or less, approximately 1×10 -11 M or less, or about 1 x 10 -12 The equilibrium dissociation constant (K D ), typically with non-specific antigens (e.g., BSA, casein Its K for binding to D At least 100 times lower than D The antigen or the antigen in the The dissociation constant can be measured using known protocols. However, antibodies that bind to an antigen or an epitope within an antigen may bind to other related antigens, e.g. or monkeys, e.g., Macaca fascicularis (cynomolgus monkey, cynopsis o), or other species such as Pan troglodytes (chimps) Monospecific antibodies may have cross-reactivity against the same antigen (homolog) from which they are derived. , which bind to one antigen or one epitope, whereas bispecific antibodies bind to two different antigens. Or it binds to two different epitopes.

[0037] "Antibody" is intended in a broad sense to include murine, human, humanized, and chimeric monoclonal antibodies. Monoclonal antibodies, antigen-binding fragments, bispecifics, trispecifics, tetraspecifics, etc. Multispecific antibodies, dimeric, tetrameric or polymeric antibodies, single chain antibodies, antibody domains and any other modification of the immunoglobulin molecule to contain an antigen-binding site of the required specificity. "Full-length antibodies" include immunoglobulin molecules that contain a structure that is bounded by disulfide bonds. It consists of two heavy chains (HC) and two light chains (LCH), which are interconnected by Each heavy chain is composed of a heavy chain variable region (HLC), and a polymer thereof (e.g., IgM). avy chain variable region (VH), and heavy chain constant region (domain CH1, hinge, Each light chain is composed of a light chain variable region (CH2, CH3, and CH4). It consists of a light chain constant region (CL) and a light chain variable region (VL). The VH and VL regions are composed of framework regions (FR) interspersed with complementarity determining regions ( Each VH and VL can be further divided into hypervariable regions called CDRs. From the carboxy terminus, the order is: FR1, CDR1, FR2, CDR2, FR3 It is composed of three CDR and four FR segments arranged as CDR1, CDR2, and FR3. can be.

[0038] A "complementarity determining region" (CDR) is the region of an antibody that binds to an antigen. at(Wu et al. (1970) J Exp Med 132:211-50) (Kabat et al., Sequences of Proteins of Immunological Interest,5th Ed.Public Hea National Institutes of Health h, Bethesda, Md., 1991), Chothia (Chothia et al. al. (1987) J Mol Biol 196:901-17), IMGT ( Lefranc et al.(2003) Dev Comp Immunol 27 :55-77), and AbM (Martin and Thornton (1996 ) J Bmol Biol 263:800-15) The correspondence between the various descriptions and the numbering of the variable regions is given (e.g. , Lefranc et al. (2003) Dev Comp Immunol 2 7:55-77, Honegger and Pluckthun, (2001) J Mol Biol 309:657-70, International Immuno GeneTics (IMGT) database; web resource, http: / / www imgt_org). abYsi by UCL Business PLC CDRs can be delineated using available programs such as those described herein. When used, "CDR", "HCDR1", "HCDR2", "HCDR3", "LC The terms "LCDR1," "LCDR2," and "LCDR3" are used unless expressly stated otherwise herein. Unless otherwise stated, the methods of Kabat, Chothia, IMGT, or AbM, as described above, It includes CDRs defined by any of the above.

[0039] Immunoglobulins are divided into five major classes, depending on the amino acid sequence of the heavy chain constant domain: IgA and IgD can be assigned to IgE, IgG, and IgM. IgG isotypes include IgA1, IgA2, IgG1, IgG2, IgG3 and Ig The antibody light chain of any vertebrate species has a constant domain of Based on the amino acid sequence, there are two distinct types: kappa (κ) and lambda (LA). λ can be assigned to one of the two

[0040] "Antigen-binding fragment" refers to a portion of an immunoglobulin molecule that binds to an antigen. The fragment may be a synthetic polypeptide, an enzymatically accessible polypeptide, or a genetically engineered polypeptide. and may be a polypeptide, such as VH, VL, VH and VL, Fab, F(ab')2, Fd, or and Fv fragments, domain antibodies (dAbs) consisting of one VH domain or one VL domain. ), shark variable IgNAR domain, camelized VH domain, FR3-CDR3-FR4 The smallest recognition unit consisting of amino acid residues that reproduce the CDR of an antibody, such as the HCDR1 portion , HCDR2, and / or HCDR3, and LCDR1, LCDR2, and / or LCDR4. The VH and VL domains are linked to each other via a synthetic linker, and various Various types of single chain antibody designs can be generated, in which the VH and VL domains are distinct When expressed by a single chain antibody construct, the VH / VL domains may be expressed intramolecularly or intermolecularly. and forming a monovalent antigen-binding site, e.g., a single chain Fv (scFv) or Bispecific antibodies can be formed and these are described, for example, in WO 1998 / 4400 1, 1988 / 01649, 1994 / 13804, and 1992 / This is described in No. 01047.

[0041] A "monoclonal antibody" is a substantially homogenous population of antibody molecules (i.e., The individual antibodies that are produced may be modified in a variety of ways, including known modifications such as removal of the C-terminal lysine from the antibody heavy chain. or amino acid isomerization or deamidation, methionine oxidation, or asparagine or glutamate oxidation. The antibody is identical to that obtained from a human mouse model except for post-translational modifications such as glutamate deamidation. Monoclonal antibodies typically bind to one antigenic epitope. Clonal antibodies bind to two different antigenic epitopes. Monoclonal antibodies are There may be heterogeneous glycosylation within an antibody population. Monoclonal antibodies are monospecific. or may be multispecific, such as bispecific, and may be monovalent, bivalent, or multivalent. That's fine.

[0042] A "humanized antibody" is an antibody in which at least one CDR is derived from a non-human species and at least one FRAP is Humanized antibodies refer to antibodies whose framework is derived from human immunoglobulin sequences. The framework can contain substitutions so that it can be used in expressed human immunoglobulins. Or may not be an exact copy of the human immunoglobulin germline gene sequence.

[0043] A "human antibody" is an antibody that is optimized to elicit a minimal immune response when administered to a human subject. Human antibodies refer to antibodies that have been engineered to be human. The variable regions of a human antibody are derived from human immunoglobulin sequences. If the antibody contains a constant region or a portion of a constant region, the constant region may also contain human immunoglobulin sequences. Human antibodies are antibodies in which the variable regions of the human antibody are derived from human germline immunoglobulins or rearrangements. If obtained from a system that uses immunoglobulin genes that have been modified, the sequence is considered to be "derived" from a human source. An exemplary such system includes a heavy chain variable region and a light chain variable region that are "displayed on a phage." The human immunoglobulin gene library and the human immunoglobulin locus "Human antibodies" includes transgenic non-human animals, such as mice or rats, that possess human antibodies. The differences in the systems used to obtain human antibodies and human immunoglobulin loci typically the deliberate introduction of somatic mutations or substitutions into the framework or CDRs; or both, resulting in amino acid differences when compared to human-expressed immunoglobulins. Typically, a "human antibody" is a human antibody that contains human germline immunoglobulins or rearranged or modified human antibodies. The amino acid sequence encoded by the immunoglobulin gene is Columns are at least approximately 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some cases, a "human antibody" is a human antibody, e.g., et al., (2000) J Mol Biol 296:57-86 Consensus framework sequences obtained from human framework sequence analysis, or e.g. Shi et al., (2010) J MolBiol 397:385-96 and The human immunoglobulins displayed on phage as described in International Publication No. 2009 / 085462 are The library may contain a synthetic HCDR3 incorporated into the purine gene library. Antibodies in which the CDRs are derived from non-human species are not included in the definition of "human antibody."

[0044] "Recombinant" refers to the joining of segments from different sources to produce recombinant DNA, antibodies, or When producing a protein, it is prepared, expressed, produced, or isolated by recombinant means. Refers to DNA, antibodies, and other proteins.

[0045] "Bispecific" refers to a molecule that is specific for two different antigens or two different epitopes on the same antigen. Bispecific antibodies refer to antibodies that bind to different antigens. Bispecific antibodies can bind to different antigens, e.g., human or monkey, For example, Macaca cynomolgus (cynomolgus) or Pan troglodytes, and other species (homologs) that have cross-reactivity to the same antigen. Alternatively, it may bind to an epitope that is shared between two or more different antigens.

[0046] "Multispecific" refers to the identification of two or more different antigens or two or more different epitopes within the same antigen. Multispecific antibodies are antibodies that specifically bind to other related antigens, e.g., human young Or monkeys, e.g., Macaca cynomolgus (cynomolgus) , or the same antigen (homolog) from other species, such as Pan troglodytes may have cross-reactivity against, or may have an endogenous antigen shared between two or more different antigens. capable of binding to a pitope.

[0047] "Macrophage" means a cell of bone marrow origin. Macrophages are primarily found in connective tissue and are large white blood cells that reside in the bloodstream or in tissue or tumor microenvironments. They ingest foreign bodies and infectious microorganisms by phagocytosis and have antigen-presenting capabilities. Non-activated macrophages derived from the body undergo specific differentiation depending on the local tissue environment. Activated macrophages react with damaged cells, activated lymphocytes, or microbial products in the tissues. In response to environmental factors, monocytes differentiate into different functional phenotypes. For example, blood monocytes differentiate into different functional phenotypes in response to inflammation or During invasion, they can enter tissues and, depending on the local microenvironment, polarize to M1 or M2 phenotypes The M1 macrophage phenotype is characterized by the production of high levels of proinflammatory cytokines, resistance to pathogens, and ability to mediate resistance to microbial infections, strong microbicidal properties, and high levels of reactive nitrogen and oxygen intermediates. It is characterized by its production, promotion of Th1 responses, and killing of pathogens and tumor cells. M2 macrophages play important roles in parasite control, tissue remodeling, immunoregulation, tumor promotion, and M2 macrophages are characterized by their involvement in efficient phagocytic activity. M2 macrophages are classified into M2a, M2b, and M2 It is further classified into four different subtypes called M2a, M3a, M4a, M5a, M6a, M7a, M8a, M9a, M10a, and M11a. "Phage" includes all macrophage subtypes.

[0048] Monocytes are a type of white blood cell involved in the first line of defense. + CD34 - single Refers to nuclear leukocytes and is recognized as capable of differentiating into dendritic cells or macrophage precursors Monocytes normally migrate through the blood system. In response to external stimulatory signals, monocytes They secrete many immunomodulatory cytokines and target the infected or tumor sites in tissues. Specifically, monocytes express elevated levels of CD14 and differentiate into macrophages. They express surface antigen markers, CD64, CD93, CD180, CD328, CD329, or peanut agglutinin protein (PNA). The present invention relates to a method for the expression of carcinoma.

[0049] "Enhance" or "induce" refers to an effect that is different from a control (e.g., a drug that enhances macrophage activity). When compared to the enhancement in the presence or absence of the drug, 0%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 9 More than 7%, 98%, 99%, or 100%, or a statistically significant difference between the macrophages The term "enhancing" refers to enhancing one or more functions or activities of a polypeptide.

[0050] "Enhancing macrophage activity" refers to the phenotypic change of monocytes and / or the macrophage activation of monocytes. Induce macrophage differentiation into phages or activate non-activated macrophages The term "enhancement of one or more macrophage activities" refers to the enhancement of one or more macrophage activities.

[0051] "Macrophage activity" refers to phagocytosis, antigen presentation, IL-12, IL-1, and TNFα. Production, or CXCL1, CXCL2, CXCL3, CXCL5, CXCL8, CXCL9 , CXCL10, CCL2, CCL3, CCL4, CCL11, CCL17, CCL22 This refers to any macrophage function, such as the production of inflammatory chemokines such as inflammatory cytokines (eg, inflammatory cytokines), and cytokine agonists (eg, inflammatory cytokines).

[0052] "Drugs that enhance macrophage activity" include small molecules, peptides, oligopeptides, and polypeptides. Peptides, proteins, antibodies, synthetic binding molecules, aptamers, RNA molecules, DNA molecules, The polymer may be a oligomer, polymer, lipid, or liposome. Potentiating agents include cytokines, chemokines, pattern recognition receptor ligands, and hormone receptors. Monones, adrenergic and cholinergic agonists, fatty acids, phospholipids, immunoglobulins phosphorylation or a part thereof, Fc domain of immunoglobulin, lipopolysaccharide (LPS), toll-like Receptor (TLR) ligands, histamine, and peroxisome proliferator-activated receptors Ligands are included.

[0053] Trogocytosis is the transfer of part of the cell membrane from a donor cell to an acceptor cell. Typical acceptor cells include macrophages and Additional acceptor cells include NK cells, dendritic cells, T cells, B cells, and monocytes. Trogocytosis-mediated movement of a portion of the cell membrane is For example, membrane proteins such as EGFR or c-Met, or antibodies that bind to cell surface molecules. Antibody-mediated trogocytosis can involve the transfer of bound antibody-antigen complexes. The Fc portion of the antibody binds to Fcγ receptors (FcγR) expressed on acceptor cells. This can occur by

[0054] "Anti-EGFR / c-Met antibody-mediated trogocytosis" refers to the process of endothelial cell membrane invasion by the donor cell. The antibody binds to EGFR and / or c-Met in the presence of EGFR / c-Met antibodies. Translocation of EGFR and / or c-Met from donor cells to acceptor cells via This refers to partial trogocytosis.

[0055] The "threshold" is the threshold for determining whether a given gene is present in a biological sample from a population of subjects with EGFR or c-Met positive cancer. macrophages or monocytes at or above the 30th percentile of those observed in This refers to the level of lymphocytes or monocytes.

[0056] An "agonist" is an agent that, when bound to a cellular protein, inhibits the natural ligand of the protein. At least one of the molecules that induces at least one reaction or activity induced by the is induced in the absence of an agonist (e.g., a negative control). At least about 20%, 30%, 40%, 45% greater than at least one reaction or activity , 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% more induced, or compared to induction in the absence of agonist. If the induction is statistically significant, then the molecule is an agonist.

[0057] An "antagonist" or "inhibitor" is a compound that, when bound to a cellular protein, inhibits the activity of the protein. A molecule that inhibits at least one response or activity induced by a natural ligand of a substance. At least one response or activity is absent in the absence of an antagonist (e.g., a negative At least one reaction or activity that is inhibited by at least about 20%, 30%, or more than at least one reaction or activity that is inhibited by ... %, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85 %, 90%, 95%, or 100% greater inhibition, or in the absence of antagonist. If the inhibition is statistically significant compared to inhibition in the absence of It is.

[0058] "PD-(L)1 axis inhibitor" refers to a molecule that inhibits PD-1 downstream signaling. D-(L)1 axis inhibitors are molecules that bind to PD-1, PD-L1, or PD-L2. That's fine.

[0059] A "biological sample" refers to a fluid, cell, or tissue isolated from a subject, as well as any sample obtained from the body of a subject. An exemplary sample refers to a collection of fluids, cells, or tissues present in a biological fluid, e.g. For example, blood, serum and serous fluid, plasma, lymph, urine, saliva, cyst fluid, tears, feces, sputum, Mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleural cavity, pericardial cavity, peritoneal cavity, abdominal cavity, and others fluids from body cavities, fluids recovered by bronchial lavage, synovial fluids, objects or biological sources, e.g. For example, liquids that come into contact with cell and organ culture media, including conditioned media of cells or organs, washing solutions, etc. solution, tissue biopsy, tumor tissue biopsy, tumor tissue sample, fine needle aspirate, surgically resected The culture medium may be a tissue, an organ culture or a cell culture.

[0060] "Low fucose" or "low fucose content" as used herein means about 1% to 15% Refers to an antibody having a fucose content.

[0061] "Normal fucose" or "normal fucose content" as used herein means about 5 0%, typically greater than about 80% or greater than 85% fucose content. Refers to antibodies.

[0062] Methods of the Disclosure JNJ-61186372 (JNJ-372) is a U.S. Patent No. 9,593,164 It is an IgG1 anti-EGFR / c-Met bispecific antibody that has been described in previous studies. Therefore, JNJ-372 acts by three different mechanisms: by blocking ligand binding to each receptor; Inhibition of ligand-induced activation via ATPase, inactivation of the receptor via degradation, and ADCC and Fc effector-mediated killing of EGFR- and c-Met-expressing tumors by EGFR and ADCP It has been shown to inhibit tumor growth and progression (Moores et al., Ancer Research 76(13), 2016.; May 23, 2016 Published online; DOI:10.1158 / 0008-5472).

[0063] The present invention not only demonstrates that JNJ-372 Fc interactions mediate ADCC and ADCP, but also It also enhanced JNJ-372-mediated inhibition of EGFR / c-Met signaling. In addition, monocytes or macrophages mediate JNJ-372 through trogocytosis. Based at least in part on the surprising finding that IL-1 is sufficient and necessary for the antitumor effect of Ku.

[0064] Without wishing to be bound by any theory, the surprising results disclosed herein Based on the results, the levels of monocytes in the patient's blood were higher than the levels of macrophages in the patient's tumors. It can be predicted that the level of JNJ-372 may be positively correlated with the level of Similarly, IHC or immune gene signatures can predict a better response to Increased levels of macrophages due to FcγRI or FcγRIII Tumor tissue samples with increased levels of a may provide more immune cell interactions. It can be predicted that patients will respond better to JNJ-372. Based on the results described herein, macrophages used in combination with JNJ-372 Treatments that enhance the activity of this peptide are expected to increase the overall efficacy of JNJ-372. For example, treatment with GM-CSF can induce the conversion of circulating monocytes into tumor-associated macrophages. This may drive differentiation of CD47-positive cells, thereby increasing the efficacy of JNJ-372. Treatment with α-aminobutyric acid blocks the negative inhibition of macrophages, thereby activating macrophages. Similarly, inhibition of the PD-(L)1 axis can enhance JNJ-372 activity. Inhibition of HDACs, or stimulation of CD11b shifts the polarization of tumor-associated macrophages This results in higher macrophage activity and therefore JN It acts synergistically with J-372 treatment to enhance tumor killing.

[0065] Identification of this novel mechanism may be achieved by detecting the relative or absolute monocyte and / or Selection of patients for treatment who are more likely to respond to JNJ-372 based on macrophage load and combination therapy using molecules that enhance macrophage activity in combination with JNJ-372. Provides a benchmark for therapy.

[0066] The present disclosure provides a method of treating a subject having an EGFR or c-Met expressing cancer, comprising administering to said subject A therapeutically effective amount of isolated macrophages in combination with an agent that enhances macrophage activity in elephants. Bispecific epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody The method includes administering to a subject

[0067] The present disclosure also provides methods for treating EGFR-related disorders that respond to treatment with bispecific anti-EGFR / c-Met antibodies. or a method for diagnosing and treating a subject having a c-Met-expressing cancer, comprising: Providing a sample and measuring macrophage or monocyte levels from the biological sample. When the level of macrophages or monocytes from the biological sample is greater than the threshold, the subject is diagnosed with a bispecific EGFR or c-Met expressing cancers that respond to treatment with heterologous anti-EGFR / c-Met antibodies and diagnosed as responding to treatment with anti-EGFR / c-Met antibody. The bispecific anti-EGFR / c-Met antibody is administered or offered for administration to the subject. and providing a method for detecting the presence of a fluorine-containing compound.

[0068] The present disclosure also relates to subjects suspected of having or having an EGFR or c-Met expressing cancer. A method of treating an elephant with a bispecific anti-EGFR / c-Met antibody, comprising: determining that the subject has a macrophage or monocyte level higher than a threshold; Subjects determined to have phage or monocyte levels were administered the bispecific anti-EGFR / c-Me and administering or providing for administration an antibody to said subject.

[0069] The present disclosure also provides methods for treating EGFR or c-Met disorders using bispecific anti-EGFR / c-Met antibodies. The present invention relates to a method for predicting the response of a subject having a c-Met-expressing cancer, the method comprising: providing a biological sample; measuring macrophage or monocyte levels from the biological sample; A subject is a responder when the level of macrophages or monocytes from the body sample is greater than a threshold value. and predicting that the

[0070] The present disclosure also provides methods for treating EGFR-related disorders that respond to treatment with bispecific anti-EGFR / c-Met antibodies. or a method of treating a subject having a c-Met-expressing cancer, comprising providing a biological sample from the subject. measuring a level of macrophages or monocytes from the biological sample; When the macrophage or monocyte levels from the sample are above a threshold, the subject is treated with bispecific anti-EGF and treating with a FR / c-Met antibody.

[0071] The present disclosure also provides a method for treating a subject with an EGFR or c-Met expressing cancer, comprising administering to the subject a bispecific anti-EGFR and determining whether the subject responds to treatment with a c-Met antibody, and whether to treat the subject. A method for isolating macrophages from a subject, the method comprising providing a biological sample from a subject and extracting macrophages from the biological sample. and measuring macrophage or monocyte levels from a biological sample. When the level is higher than the threshold, the subject with EGFR or c-Met expressing cancer is or by detecting a specific antibody from a biological sample. When the macrophage or monocyte level is below the threshold, EGFR or c-Met -expressing cancers do not respond to treatment with bispecific anti-EGFR / c-Met antibodies and responding to treatment with a bispecific anti-EGFR / c-Met antibody. or administering a bispecific anti-EGFR / c-Met antibody to the subject. Bispecific anti-EGFR / c-Met antibody therapy in subjects diagnosed as non-responsive to treatment and refraining from administering the c-Met antibody.

[0072] The "level" of macrophages or monocytes may be either qualitative (e.g., present or absent) or quantitative. Quantitative (e.g., absolute cell count, relative cell count, percent of total cells, or field of view) In some embodiments, the macrophages or monocytes may be viable. In some embodiments, the level of macrophages or monocytes is not present in a body sample. Above the average number of macrophages or monocytes observed in biological samples from healthy subjects. In some embodiments, the levels of macrophages or monocytes are determined by measuring EGFR or c-Met Approximately 3% of macrophages or monocytes observed in biological samples from subjects with positive cancer In some embodiments, the level of macrophages or monocytes is the 0th percentile. The present invention relates to a method for detecting EGFR- or c-Met-positive cancers. In some embodiments, the 35th percentile of macrophages or monocytes. Levels of phages or monocytes were determined from live subjects with EGFR or c-Met positive cancer. This is approximately the 40th percentile of macrophages or monocytes observed in body samples. In some embodiments, the level of macrophages or monocytes is determined to be EGFR or c-Met positive. Approximately 45% of macrophages or monocytes observed in biological samples from subjects with cancer In some embodiments, the level of macrophages or monocytes is a percentile value. , macrophages observed in biological samples from subjects with EGFR or c-Met positive cancer In some embodiments, the IL-10 expression level is about the 50th percentile of macrophages or monocytes. The levels of phage or monocytes were determined by analyzing the biomarkers from subjects with EGFR or c-Met positive cancer. This is approximately the 60th percentile of the macrophages or monocytes observed in the sample. In some embodiments, the level of macrophages or monocytes is EGFR or c-Met positive. Approximately 65% ​​of macrophages or monocytes were observed in biological samples from subjects with cancer. In some embodiments, the level of macrophages or monocytes is Macros observed in biological samples from subjects with EGFR or c-Met positive cancer In some embodiments, the phage or monocyte antibody is about the 70th percentile. Levels of phage or monocytes were measured in biopsies from subjects with EGFR or c-Met positive cancer. This is approximately the 75th percentile of macrophages or monocytes observed in the sample. In some embodiments, the level of macrophages or monocytes is determined based on EGFR or c-Met positivity. Approximately 80% of macrophages or monocytes observed in biological samples from subjects with cancer In some embodiments, the level of macrophages or monocytes is expressed as E Macrophage observed in biological samples from subjects with GFR or c-Met positive cancer In some embodiments, the phage or monocyte count is about the 85th percentile. The levels of EGFR or monocytes were measured in a biological sample from a subject with EGFR or c-Met positive cancer. This is approximately the 90th percentile of macrophages or monocytes observed in In an embodiment, the level of macrophages or monocytes is indicative of EGFR or c-Met positive cancer. Approximately 95% of macrophages or monocytes observed in biological samples from subjects with In some embodiments, the levels of macrophages or monocytes are EGFR 1 or EGFR 2 or EGFR 3 or EGFR 4 or EGFR 5 or EGFR 6 or EGFR 7 or EGFR 8 or EGFR 9 or EGFR 10 or EGFR 11 or EGFR 12 or EGFR 13 or EGFR 14 or EGFR 15 or EGFR 16 or EGFR 17 or Macrophages observed in biological samples from subjects with FR or c-Met positive cancer The values ​​are approximately the 100th percentile for lymphocytes or monocytes.

[0073] Macrophage or monocyte levels in subjects with EGFR or c-Met expressing cancer The levels of macrophages or monocytes in biological samples from healthy subjects were compared. Increased levels of macrophages or monocytes may be obtained, for example, from biopsies from healthy subjects. When compared to the levels of macrophages or monocytes in the sample, times, approximately 3 times, approximately 3.5 times, approximately 4 times, approximately 4. times, approximately 5 times, approximately 5.5 times, approximately 6 times, approximately 6.5 times , about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, or about 10-fold higher. .

[0074] Macrophages express, for example, CD68, iNOS (inducible nitric oxide synthase), and CD163 is a marker for pan-macrophages, M1 macrophages, or M2 macrophages. The percentage of areas of positive staining was assessed and compared with non-tumor tissue, e.g., using each as a marker. For example, from tumor tissue biopsies obtained from subjects with EGFR or c-Met expressing tumors. (e.g., the percent area of ​​positive staining for CD68 is different for adenocarcinoma, squamous epithelium, or It has been reported that Almatoad was increased 2-fold in large cell carcinoma compared to non-tumor. i et al., Cancer Microenvironment 9:1-11 , 2016). Macrophages, for example, use immune gene signatures from tumor tissue biopsies obtained from subjects with EGFR or c-Met expressing tumors. It can be identified.

[0075] Monocytes were identified using the monocyte marker CD14 and using fluorescent cell sorting to identify EGFR or c- It can be identified from blood samples from subjects with Met-expressing tumors.

[0076] In some embodiments, the biological sample is a blood sample.

[0077] In some embodiments, the biological sample is a tumor tissue biopsy.

[0078] Similarly, by providing more immune cell interactions, Levels of FcγRI or FcγRIIIa may be used to predict patient response. stomach.

[0079] In some embodiments, the levels of FcγRI or FcγRIIIa are determined from healthy subjects. above the average levels of FcγRI or FcγRIIIa observed in biological samples In some embodiments, the level of FcγRI or FcγRIIIa is The FcγRI or Fcγ expression levels observed in biological samples from subjects with c-Met-positive cancer In some embodiments, the Fcγ expression level is about the 30th percentile of the Fcγ expression level. The levels of RI or FcγRIIIa were significantly higher in subjects with EGFR or c-Met positive cancers. Approximately 35% of the levels of FcγRI or FcγRIIIa observed in these biological samples. In some embodiments, the level of FcγRI or FcγRIIIa is FcγR observed in biological samples from subjects with EGFR or c-Met positive cancer In some embodiments, the level of FcγRIIIa or FcγRIIIa is about the 40th percentile. So, the levels of FcγRI or FcγRIIIa are important predictors of EGFR- or c-Met-positive cancer. Approximately the levels of FcγRI or FcγRIIIa observed in biological samples from subjects with In some embodiments, FcγRI or FcγRIII Levels of a are observed in biological samples from subjects with EGFR or c-Met positive cancers. The levels of FcγRI or FcγRIIIa obtained are approximately the 50th percentile. In some embodiments, the level of FcγRI or FcγRIIIa is indicative of EGFR or c-Me FcγRI or FcγRIIIa observed in biological samples from subjects with t-positive cancer In some embodiments, the FcγRI or FcγRI antibody is about the 60th percentile of the FcγRI or FcγRI antibody levels. Levels of cγRIIIa were measured in biopsies from subjects with EGFR or c-Met positive cancers. At approximately the 65th percentile of FcγRI or FcγRIIIa levels observed in the samples In some embodiments, the level of FcγRI or FcγRIIIa is or FcγRI or FcγRI observed in biological samples from subjects with c-Met positive cancer. In some embodiments, the Fc The levels of FcγRIIIa or FcγRIIIa were measured in subjects with EGFR or c-Met positive cancer. Approximately 75% of the levels of FcγRI or FcγRIIIa observed in biological samples from In some embodiments, the level of FcγRI or FcγRIIIa is The Fcγ expression levels observed in biological samples from subjects with EGFR or c-Met positive cancers The FcγRIIIa level is about the 80th percentile. In this study, the levels of FcγRI or FcγRIIIa were associated with EGFR- or c-Met-positive cancer. The levels of FcγRI or FcγRIIIa observed in biological samples from subjects with In some embodiments, the FcγRI or FcγRII antibody is about the 85th percentile. Levels of Ia were observed in biological samples from subjects with EGFR or c-Met positive cancer. The measured FcγRI or FcγRIIIa levels are approximately the 90th percentile. In some embodiments, the level of FcγRI or FcγRIIIa is FcγRI or FcγRIII observed in biological samples from subjects with et-positive cancer In some embodiments, the FcγRI or Levels of FcγRIIIa were assayed in vivo from subjects with EGFR or c-Met positive cancers. Approximately the 100th percentile of the levels of FcγRI or FcγRIIIa observed in the sample value.

[0080] FcγRI or FcγRIIIa levels were measured using tumor tissue samples (fresh frozen or paraffin It can be measured using immunohistochemistry in embedded tumor tissue sections, etc. The levels of FcγRI or FcγRIIIa were determined by measuring the levels of FcγRI or FcγRIII in a microscopic field. The levels of FcγRI or FcγRIIIa were also expressed as a percentage of cells. In addition, genes may be extracted from tumor tissue samples as part of an immune gene signature panel or as individual genes. RNA isolated from the cells can also be used to measure gene expression levels.

[0081] In some embodiments, the bispecific anti-EGFR / c-Met antibody is Heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, SEQ ID NO:3, light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:4, L of SEQ ID NO:5 a first domain that binds to EGFR, comprising a CDR2, an LCDR3 of sequence SEQ ID NO: 6, and HCDR1 of SEQ ID NO:7, HCDR2 of SEQ ID NO:8, HCDR3 of SEQ ID NO:9, SEQ ID NO:10 LCDR1 of SEQ ID NO: 11, LCDR2 of SEQ ID NO: 12, and a second domain that binds to Met.

[0082] In some embodiments, the first domain that binds to EGFR comprises the heavy chain of SEQ ID NO: 13. A humanized antibody that binds to c-Met and comprises a variable region (VH) and a light chain variable region (VL) of SEQ ID NO: 14. The second domain comprises a VH of SEQ ID NO:15 and a VL of SEQ ID NO:16.

[0083] In some embodiments, the bispecific anti-EGFR / c-Met antibody is an IgG1 isoform. There is some diversity within the IgG1 constant domain (e.g., the well-known allotypes). 214, 356, 358, 422, 431, 435, or 436 (EU Residue numbering according to the numbering system) (e.g., IMGT web resource; IM GT Repertoire (IG and TR);Proteins and a (See allotypes.) Bispecific anti-EGFR / c-Me The t antibody is G1m17, G1m3, G1m1, G1m2, G1m27, or G1m28. It may be of any IgG1 allotype.

[0084] In some embodiments, the bispecific anti-EGFR / c-Met antibody has the sequence of SEQ ID NO: 17. First heavy chain (HC1), first light chain (LC1) of SEQ ID NO: 18, second heavy chain (LC2) of SEQ ID NO: 19 The antibody comprises a first light chain (HC2) and a second light chain (LC2) of SEQ ID NO:20.

[0085] In some embodiments, the agent that enhances macrophage activity is GM-CSF, CD4+ 47 antagonist, anti-CD47 antibody, HDAC inhibitor, PD-(L)1 axis inhibitor, or It is a CD11b agonist.

[0086] In some embodiments, the agent that enhances macrophage activity is GM-CSF. .

[0087] In some embodiments, the agent that enhances macrophage activity is an anti-CD47 antagonist. He is a nist.

[0088] In some embodiments, the agent that enhances macrophage activity is an anti-CD47 antibody. do.

[0089] In some embodiments, the agent that enhances macrophage activity is an HDAC inhibitor. do.

[0090] In some embodiments, the agent that enhances macrophage activity inhibits the PD-(L)1 axis. It is a harmful agent.

[0091] In some embodiments, the agent that enhances macrophage activity is a CD11b agonist. It is.

[0092] In some embodiments, the HDAC inhibitor is an HDAC2 inhibitor.

[0093] An exemplary CD47 antagonist is a CD47 ligand-Fc fusion, e.g., TTI. 621 and SIRPα-Fc fusions such as anti-CD47 antibodies.

[0094] Exemplary anti-CD47 antibodies include those disclosed in WO 2016 / 081423. u5F9-G4, TI-061, TTI-622, AO-176, IBI-188, AL X-148, SRF-231, CC-90002, and anti-CD47 antibody.

[0095] Exemplary HDAC inhibitors are vorinostat, romidepsin, chidamin, panobinostat, belinstat, prasinostat, avexinostat, entinostat, Fidemstat, GSK-2879552, ricorinostat, iademstat, Domatinostat, Resminostat, AZD-9468, Nanatinostat, CG-2 00745, Mocetinostat, INCB-59872, IMG-7289, Tinostam Stin, RDN-929, YM-753, HG-146, NBM-BMX, TAK-41 8, Securidemcitat, CKD-504, CKD-506, CC-90011, KA- 2507, and citrinostat.

[0096] Exemplary PD-(L)1 axis inhibitors are nivolumab (OPDIVO®), penicillin-resistant Staphylococcus aureus (Pen ... Brolimumab (KEYTRUDA®), sintilimab, cemiplimab (LIB TAYO (registered trademark), tripolibamab, tislelizumab, spartalizumab, camre PD-1 binding agents such as rituximab, dostralimab, genolimusab, or cetrelimab or an antibody that binds to PD-L1. For example, the PD-1 antibody is Limab, atezolizumab (TECENTRIQ®), durvalumab (IMF INZI®), and avelumab (BAVENCIO®).

[0097] Commercially available antibodies can be purchased through licensed distributors or pharmacies. The amino acid sequence structures are based on company-specific USAN and / or I It can be found in the NN deposit.

[0098] In some embodiments, the EGFR or c-Met expressing cancer is characterized by wild type EGFR, EG FR activating mutations, EGFR gene amplification, elevated levels of circulating HGF, wild-type c-Met, It is associated with activating c-Met mutations, c-Met gene amplification, or mutant KRAS.

[0099] Exemplary EGFR activating mutations that may be associated with cancer include increased tyrosine kinase activity. EGFR is a novel marker for EGFR signaling, which is involved in the formation of receptor homodimers and heterodimers, as well as enhanced ligand binding. A point mutation, deletion mutation, insertion mutation, inversion, or gene amplification that increases at least one biological activity The mutation may be any of the EGFR gene or a regulatory region associated with the EGFR gene. and a mutation in exon 18, 19, 20, or 21 or a kinase domain. Other examples of EGFR activating mutations are known in the art. (See, e.g., U.S. Patent Application Publication No. 2005 / 0272083. ) Receptor homo- and heterodimers, receptor ligands, autophosphorylation sites, and ErbB EGFR and other ErbB signaling molecules involved in ErbB-mediated signal transduction Information regarding receptors is known in the art (e.g., Hynes and Lane, Nature Reviews Cancer 5:341-354,20 (See 05.)

[0100] In some embodiments, the EGFR activating mutation is L718Q, G719A, G719 X (wherein X is any amino acid), L861X (wherein X is any amino acid), L8 58R, E746K, L747S, E749Q, A750P, A755V, V765M, C797S, L858P, or T790M substitution, E746-A750 deletion, R7 Deletion of 48~P753, insertion of Ala (A) between M766 and A767, and insertion of S768 and Insertion of Ser, Val, and Ala (SVA) between V769, P772, and H773 Insertion of Asn and Ser(NS) between D761 and E762, A763 and Y764 , Y764 and Y765, M766 and A767, A767 and V768, S768 and V769 , V769 and D770, D770 and N771, N771 and P772, P772 and H773 , insertion of one or more amino acids between H773 and V774, between V774 and C775 one or more deletions or one or more insertions in EGFR exon 20 It is.

[0101] Exemplary c-Met activating mutations include increased tyrosine kinase activity, receptor homodimerization, and The formation of dimers and heterodimers and enhanced ligand binding are some of the properties of c-Met protein. point mutations, deletions, insertions, inversions, or gene amplifications that increase one or more biological activities The mutation may occur in any part of the c-Met gene or in the kinase domain of c-Met. Exemplary c-Met activating The mutations were at residue positions N375, V13, V923, R175, V136, L229, and S32 3, R988, S1058 / T1010, and E168 mutations. Methods for detecting c-Met mutations or gene amplification are well known.

[0102] In some embodiments, the mutant KRAS has a G12V, G12C, or G12A substitution. Has conversion.

[0103] In some embodiments, the subject has a newly diagnosed EGFR or c-Met expressing cancer. has.

[0104] In some embodiments, the patient has a newly diagnosed EGFR or c-Met expressing cancer. The subject has one or more EGFR exon 20 mutations. The insertion of one or more amino acids is effective against EGFR tyrosine kinase inhibitors (TKIs). are commonly resistant to ).

[0105] In some embodiments, the subject is refractory to treatment with a previous anti-cancer therapy. or have acquired resistance.

[0106] In some embodiments, the prior anti-cancer therapy is chemotherapy, targeted anti-cancer therapy, or quinine. It is an enzyme inhibitor.

[0107] In some embodiments, the kinase inhibitor is EGFR, c-Met, HER2, HE It is an inhibitor of R3, HER4, VEGFR, or AXL.

[0108] In some embodiments, the kinase inhibitor is erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, clinib Otinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib , regorafenib, pazopanib, sorafenib, or sunitinib.

[0109] In some embodiments, the subject is resistant or has a disease that is resistant to an EGFR inhibitor. Exemplary EGFR inhibitors to which cancers may develop resistance are anti-EGFR antibodies. cetuximab (ERBITUX®), pancinumumab (VECTIBI X®), matuzumab, nimotuzumab, and the small molecule EGFR inhibitor erlotinib. tetanus (TARCEVA®), gefitinib (IRESSA®), EK B-569 (pelitinib, an irreversible EGFR TKI), pan-ErbB and other receptor tyrosine kinase inhibitor Lapatinib (EGFR and HER2 inhibitor), a synthase inhibitor, and pelitinib (E GFR and HER2 inhibitors), vandetanib (ZD6474, ZACTIMA™, EGFR, VEGFR2, and RET TKI), PF00299804 (dacomitinib , irreversible pan-ErbB TKI), CI-1033 (irreversible pan-erbB TKI), Fatinib (BIBW2992, irreversible pan-ErbB TKI), AV-412 (double E GFR and ErbB2 inhibitor), EXEL-7647 (EGFR, ErbB2, GEVG R, and EphB4 inhibitor), CO-1686 (irreversible mutant selective EGFR TKI ), AZD9291 (irreversible mutant-selective EGFR TKI), and HKI-272 (Neratinib, an irreversible EGFR / ErbB2 inhibitor).

[0110] A variety of qualitative and / or quantitative methods are used to determine whether a subject responds to treatment with an anti-cancer therapy. Whether or not a plant is resistant, has developed resistance, or is likely to develop resistance Symptoms that may be associated with resistance to anti-cancer therapy include: A decrease or plateau in the patient's health, an increase in tumor size, a cessation of tumor growth or Slowing down and / or spreading cancerous tissues in the body from one location to other organs, tissues, or cells These include cell proliferation, loss of appetite, cognitive impairment, depression, difficulty breathing, fatigue, and hormone disruption. , neutropenia, pain, peripheral neuropathy, and sexual dysfunction, among other cancer-related symptoms. Re-establishment or exacerbation may also occur when a subject has developed or is susceptible to developing resistance to anti-cancer therapy. Symptoms associated with cancer may vary depending on the type of cancer. For example, Symptoms associated with cervical cancer include abnormal bleeding, abnormal heavy vaginal discharge, and regular menstrual periods. Non-cyclical pelvic pain, bladder pain or pain during urination, and pain during regular menstrual periods, sexual intercourse, Symptoms associated with lung cancer include persistent vaginal flushing, bleeding after a vaginal exam, or bleeding after a vaginal exam. Symptoms include a sore cough, coughing up blood, shortness of breath, wheezing chest pain, loss of appetite, involuntary weight loss, and fatigue. Symptoms of liver cancer include loss of appetite and weight, especially in the back and shoulders. Abdominal pain in the upper right part of the abdomen that may spread, nausea and vomiting, general weakness and fatigue, enlarged liver, abdominal Symptoms include swelling (ascites) and yellowing of the skin and whites of the eyes (jaundice). Anyone can easily identify symptoms associated with specific types of cancer.

[0111] In some embodiments, the EGFR and c-Met expressing cancer is an epithelial cell carcinoma, a breast cancer , ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, small cell lung cancer, colorectal cancer Bowel cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer , pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, cervical cancer, splenic cancer Cancer of the testis, stomach, thymus, colon, thyroid, liver, hepatocellular carcinoma (HCC) renal cell carcinoma (PRCC), or sporadic or hereditary papillary renal cell carcinoma (PRCC).

[0112] In some embodiments, the EGFR or c-Met expressing cancer is an epithelial cell cancer. In some embodiments, the EGFR or c-Met expressing cancer is breast cancer. In some embodiments, the EGFR or c-Met expressing cancer is ovarian cancer. In some embodiments, the EGFR or c-Met expressing cancer is lung cancer. EGFR or c-Met expressing cancers are non-small cell lung cancers (NSCLC). In some embodiments, the EGFR or c-Met expressing cancer is lung adenocarcinoma. In some embodiments, the EGFR or c-Met expressing cancer is small cell lung cancer. In some embodiments, the EGFR or c-Met expressing cancer is colorectal cancer. In some embodiments, the EGFR or c-Met expressing cancer is anal cancer. The EGFR or c-Met expressing cancer is prostate cancer. In some embodiments, the EGFR or c-Met expressing cancer is renal cancer. In some embodiments, the c-Met expressing cancer is bladder cancer. The Met-expressing cancer is head and neck cancer. In some embodiments, EGFR or c-Me In some embodiments, the EGFR or c-Met expressing cancer is pharyngeal cancer. The cancer is a nasal cancer. In some embodiments, the EGFR or c-Met expressing cancer is In some embodiments, the EGFR or c-Met expressing cancer is a skin cancer. In some embodiments, the EGFR or c-Met expressing cancer is oral cancer. In some embodiments, the EGFR or c-Met expressing cancer is a tongue cancer. In some embodiments, the EGFR or c-Met expressing cancer is esophageal cancer. In some embodiments, the EGFR or c-Met expressing cancer is vaginal cancer. In some embodiments, the EGFR or c-Met expressing cancer is cervical cancer. In some embodiments, the EGFR or c-Met expressing cancer is a cancer of the spleen. In some embodiments, the EGFR or c-Met expressing cancer is testicular cancer. In some embodiments, the EGFR or c-Met expressing cancer is gastric cancer. The c-Met expressing cancer is a cancer of the thymus. The Met-expressing cancer is colon cancer. In some embodiments, the EGFR or c-Met expressing cancer is thyroid cancer. The cancer is liver cancer. In some embodiments, the EGFR or c-Met expressing cancer is In some embodiments, EGFR or c-Met expression is The cancer is sporadic or hereditary papillary renal cell carcinoma (PRCC).

[0113] In some embodiments, NSCLC includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. In some embodiments, the cells of the NSCLC have an epithelial phenotype. In some embodiments, the NSCLC is resistant to treatment with one or more EGFR inhibitors. has acquired sexuality.

[0114] In NSCLC, certain mutations in the EGFR gene are involved in EGFR tyrosine kinase inhibitors. Associated with high response rates (70-80%) to EGFR TKIs. Exon 1 The five amino acid deletion in EGFR T It is related to the sensitivity of KI (Nakata and Gotoh, Expert Opinion n Ther Targets 16:771-781, 2012). These mutations are Activating EGFR mutations result in ligand-independent activation of EGFR kinase activity. It occurs in 10-30% of SCLC patients and is most prevalent in East Asians, females, never-smokers, and glandular It is significantly more common in patients with histologic evidence of cancer (Janne and Johnson Clin Cancer Res 12(14 Suppl):44 16s-4420s, 2006). EGFR gene amplification is a predictor of response to EGFR TKI treatment. It also correlates strongly with the response to chemotherapy (Cappuzzo et al., J Natl Cancer Inst 97:643-55,2005). EGFR exon 20 insertions are Associated with TKI resistance.

[0115] The majority of patients with EGFR-mutated NSCLC initially respond to EGFR TKI therapy. However, virtually all develop resistance that prevents a sustained response in 50-60% of patients. Resistance to EGFR is due to a second site point mutation (T790M) in the kinase domain of EGFR. Nearly all tumors that have become resistant to EGFR tyrosine kinase inhibitors In 60% of cases, c-Met expression is increased, c-Met is amplified, or its only known link is The level of HGF, a cancer growth factor, increases (Turke et al., Cancer Cell, 17:77-88,2010).

[0116] In some embodiments, the subject is mutated to phenylalanine at position 158 of CD16. or are heterozygous for valine and phenylalanine at position 158 of CD16. It is of the b-junction type.

[0117] Subjects who are homozygous for phenylalanine at position 158 of CD16 are They have the γRIIIa-158F / F genotype. Subjects who are heterozygous for phenylalanine have the FcγRIIIa-158F / V CD16 has the genotype Fc gamma receptor IIIa (FcγRIIIa) or low Affinity immunoglobulin gamma Fc region receptor also known as III-A isoform The valine / phenylalanine ( It has been shown that the V / F polymorphism affects FcγRIIIa affinity for human IgG. FcγRIIIa-158F / F or FcγRIIIa-158F / V polymorphism Receptors with reduced Fc binding compared to FcγRIIIa-158V / V and therefore exhibit reduced ADCC. Low amounts of fucose result in improved binding of the antibody to human FcγRIIIa (CD16). , improving the ability of antibodies to induce ADCC (Shields et al., J Biol. ol Chem 277:26733~40, 2002).

[0118] In some embodiments, the bispecific anti-EGFR / c-Met antibody is % of low fucose content. Bispecific anti-EGFR / c-Me with low fucose content The t antibody is a FcγRIIIa-158F / F or FcγRIIIa-158F / V gene. Using routine methods, patients can be treated with Fcγ One can analyze for the RIIIa polymorphism.

[0119] Antibodies with low fucose content can be used to control the osmolarity of the culture (Konno et al., Cytotechnology 64(:249-65,2012) as a host cell line Application of the variant CHO strain Lec13 (Shields et al., J Biol Chem 277:26733-26740,2002), as a barrier to host cell lines Application of the human CHO strain EB66 (Olivier et al., MAbs; 2(4), 2 010; Electronic publication prior to printing, PMID:20562582), Rat hybridoma Application of cell line YB2 / 0 as a host cell line (Shinkawa et al., JB iol Chem 278:3466-3473,2003), α1,6-fucosyltransferase Introduction of small interfering RNA specific for the Mori transduction enzyme (FUT8) gene et al.,Biotechnol Bioeng 88:901-908,200 4) or β-1,4-N-acetylglucosaminyltransferase III and Kifunensine, a potent inhibitor of Golgi α-mannosidase II and α-mannosidase I Co-expression of (Ferrara et al., J Biol Chem 281:5032- 5036,2006, Ferrara et al.,Biotechnol Bioe ng93:851-861,2006, Xhou et al.,Biotechnol Biantennary complex Fc oligosaccharides such as It has been reported that this leads to the efficient expression of relatively highly defucosylated antibodies with The method can be obtained using a variety of methods known in the art.

[0120] In some embodiments, the subject is further administered a third anti-cancer therapy.

[0121] In some embodiments, the third anti-cancer therapy is a chemotherapy, a targeted anti-cancer therapy, or a quinine. It is an enzyme inhibitor.

[0122] In some embodiments, the kinase inhibitor is EGFR, c-Met, HER2, HE In some embodiments, the inhibitor is an inhibitor of KCR4, HER4, VEGFR, or AXL. The kinase inhibitor is an inhibitor of EGFR. In some embodiments, the kinase inhibitor is In some embodiments, the kinase inhibitor is an inhibitor of HER2. In some embodiments, the kinase inhibitor is an inhibitor of HER3. In some embodiments, the kinase inhibitor is an inhibitor of HER4. In some embodiments, the kinase inhibitor is an inhibitor of VEGFR. The enzyme inhibitor is also an inhibitor of AXL.

[0123] In some embodiments, the kinase inhibitor is erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, clinib Otinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib , regorafenib, pazopanib, sorafenib, or sunitinib.

[0124] In some embodiments, the kinase inhibitor is erlotinib. In some embodiments, the kinase inhibitor is gefitinib. In some embodiments, the kinase inhibitor is vandetanib. In some embodiments, the kinase inhibitor is afatinib. In embodiments, the kinase inhibitor is osimertinib. In some embodiments, the kinase inhibitor is lazertinib. In some embodiments, the kinase inhibitor is cilotinib. In some embodiments, the kinase inhibitor is cabozantinib. In some embodiments, the kinase inhibitor is capmatinib. In some embodiments, the kinase inhibitor is axitinib. In some embodiments, the kinase inhibitor is nintedanib. In some embodiments, the kinase inhibitor is regorafenib. The kinase inhibitor is pazopanib. In some embodiments, the kinase inhibitor is sozopanib. In some embodiments, the kinase inhibitor is sunitinib.

[0125] The methods of the disclosure may be administered in combination with a bispecific anti-EGFR / c-Met antibody. The anti-cancer therapy may include any of a chemotherapeutic agent or other anti-cancer therapeutic agent known to those of skill in the art. A chemotherapeutic agent is a chemical compound useful in the treatment of cancer. Antiproliferative agents or other cytotoxic agents, including alkylating agents, antimetabolites, antimicrotubule inhibitors, topoisomers, These include isomerase inhibitors, receptor tyrosine kinase inhibitors, and angiogenesis inhibitors. Examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclophosphamide (C YTOXAN®, etc.; alkyl sulfonates, such as busulfan, impurities, etc. aziridines such as benzodopa, carboquone, methacin, benzosulfan ... Turedopa, uredopa, etc.; altretamine, triethylenemelamine, triethylenephosphatase ethyl esters including sulfuramide, triethylenethiophosphoramide and trimethylolmelamine methylamelamine; nitrogen mustards, e.g. For example, chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosulfan Famide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembiti phenesterine, prednimustine, trofosfamide, uracil mustard, etc.; Nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, Nimustine, Ranimustine, etc.; Antibiotics, such as aclacinomycin ), actinomycin, autramycin, azaserine, bleomycin Cactinomycin, calicheamicin, carabicin, carminomycin , carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, Sorubicin, idarubicin, marcellomycin, mitomycin, Cophenolic acid, nogalamycin, olivomycin, peplomycin, pothophyllomycin Potfiromycin, puromycin, quelamycin, rodorubicin (rodorubicin), streptonigrin, streptozocin, tubercidin, ubenimec antimetabolites such as methotrexate and 5-F U, etc.; folic acid analogues, e.g. denopterin, methotrexate, pteropterin, trime treoxate, etc.; purine analogues, e.g. fludarabine, 6-mercaptopurine, thiamine Purines, thioguanine, etc.; pyrimidine analogues, e.g. ancitabine, azacytidine, 6 -Azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, Enocitabine, floxuridine, etc.; androgens, e.g. calsterone, propionate dromostanolone acid, epithiostanol, mepitiostane, testolactone, etc.; adrenal Corticosteroid synthesis inhibitors, such as aminoglutethimide, mitotane, trilostane, etc. Acid replenishers, such as folinic acid; Graton;Aldophosphamide glycosides;Aminolevulinic acid;Amsacrine;Bestra Bucil; Bisantrene; Edatraxate; Defofamine ); Demecolcine; Diaziquone; Elfornithine; Elliptinium elliptinium acetate; etoglucide; gallium nitrate; hydroxyurea; Lentinan; Lonidamine; Mitoguazone; Mitoxantrone; Mopidamol; Nitracriptine pentostatin; phenameth; pirarubicin; podophyllic acid; 2-ethylhydrazine Zide; Procarbazine; PSK (registered trademark); Razoxane; Sizofiran; Spirogerma nium;tenuazonic acid;triaziquone;2,2',2"-trichloro Triethylamine; Urethane; Vindesine; Dacarbazine; Mannomustine; Mitobromine Thor; Mitolactol; Pipobroman; Gacytosine; Arabinoside (" Ara-C); cyclophosphamide; thiotepa; taxoid or taxane family Members such as paclitaxel (TAXOL®), docetaxel (TAXOTE®), RE(R) and its analogs; Chlorambucil; Gemcitabine; 6-Thioguanine mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin vinblastine; platinum; etoposide (VP-16); ifosfamide; myeloma Tomycin C; Mitoxantrone; Vincristine; Vinorelbine; Navelbine; Novan Thoron;teniposide;daunomycin;aminopterin;xeloda;ibandronate; CPT-11; Topoisomerase inhibitor RFS2000; Difluoromethylornithine ( DMFO; retinoic acid; esperamicin; capecitabine; sorafenib (NEXAV AR®), sunitinib (SUTENT®), pazopanib (VOTR®), IENT™), toceranib (PALLADIA™), vandetanib (ZAC TIMA™), cediranib (RECENTIN®), regorafenib ( BAY73-4506), axitinib (AG013736), lestaurtinib (CE P-701), erlotinib (TARCEVA®), gefitinib (IRES SA), afatinib (BIBW 2992), lapatinib (TYKERB Receptor tyrosine kinase and / or are inhibitors of angiogenesis, as well as pharma- ceutical acceptable salts, acids, or derivatives of any of the above. Anti-hormonal agents that act to regulate or inhibit hormone action on tumors. , e.g. tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazoles, 4-Hydroxytamoxifen, trioxifene, ketoxifen FARESTON, LY 117018, onapristone, and toremifene (FARESTON( antiestrogens, including benzodiazepines, benzodiazepines, etc.; as well as antiandrogens, such as flutamide , nilutamide, bicalutamide, leuprolide and goserelin; and any of the above Also included within this definition are physiologically acceptable salts, acids or derivatives. al.,1985,Medical Oncology(Calabresi et al. aL, eds.), Chapter 10, McMillan Publishing. Other common cytotoxic compounds as described are also applicable to the methods of the present invention. do.

[0126] Administration The bispecific anti-EGFR / c-Met antibody and macrophage activator were combined in a mixture. The compositions may be administered to a subject simultaneously as single agents, or sequentially as single agents in any order.

[0127] In some embodiments, the bispecific anti-EGFR / c-Met antibody is It is administered prior to administration of the activating agent.

[0128] In some embodiments, the bispecific anti-EGFR / c-Met antibody is It is administered after administration of the activating agent.

[0129] In some embodiments, the bispecific anti-EGFR / c-Met antibody is It is administered simultaneously with the administration of the activator.

[0130] In some embodiments, the bispecific anti-EGFR / c-Met antibody is is administered prior to administration of

[0131] In some embodiments, the bispecific anti-EGFR / c-Met antibody is It is administered after administration of.

[0132] In some embodiments, the bispecific anti-EGFR / c-Met antibody is is administered simultaneously with administration of

[0133] Bispecific anti-EGFR / c-Met antibody and macrophage activator or third anti-cancer agent The length of time between administration of the therapy may be several minutes, for example, about 1, 2, 5, 10, 30, or 6 60 minutes, or for several hours, e.g., about 2, 4, 6, 10, 12, 24, or 36 hours; Or, for example, for about 2, 4, 7, 14, 21, 28, 35, 42, 49, 56 days or more. obtain. Bispecific anti-EGFR / c-Met antibody and macrophage activator or third anti-cancer agent The agent may be administered in a pharma- ceutical acceptable carrier. A "carrier" is a compound that is administered together with the antibody of the present invention. The term "diluent," "adjuvant," "excipient," or "vehicle" refers to a diluent, adjuvant, excipient, or vehicle that is administered to a subject. Such vehicles include water, and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, and mineral oil. For example, 0.4% saline and 0.3% glycine may be used. These solutions may be used to formulate bispecific anti-EGFR / c-Met antibodies. They are sterile and generally free of particulate matter. They can be sterilized by conventional, well-known sterilization techniques (e.g., It can be sterilized by filtration. For oral solid preparations such as powders, capsules, and tablets, In this case, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, etc. The oral solid preparation may be coated with a substance such as sugar. In the case of parenteral administration, the drug may be enterically coated to regulate the main absorption site. In this case, the carrier may comprise sterile water, and other excipients may be added to enhance solubility or for preservation. Injectable suspensions or solutions may also be prepared using aqueous carriers together with suitable additives. Suitable vehicles and formulations containing other human proteins, such as human serum albumin, are For example, Remington: The Science and Practice of Pharmacy, 21 st Edition, Troy, DBed., Li pincott Williams and Wilkins,Philadelphia a,PA 2006,Part 5,Pharmaceutical Manufacturer during pp691-1092, with particular reference to pp.958-989. stomach.

[0134] The composition may comprise pharma- ceutically acceptable auxiliary substances required to approximate physiological conditions, For example, pH adjusting and buffering agents, stabilizers, thickening agents, lubricants, and coloring agents may be contained. Concentrations of bispecific anti-EGFR / c-Met antibody and macrophage activator in pharmaceutical formulations is from less than about 0.5% by weight, usually at least about 1% by weight, up to 15% by weight, 20% by weight, %, 30%, 40%, or 50% by weight, and may vary depending on the particular composition selected. The dosage form may be selected based primarily on the required dose, fluid volumes, viscosities, etc., according to the intended mode of administration. The pharmaceutical composition comprising the solid form may contain from about 0.1 mg to about 2000 mg, for example, about 1 mg, about 5 mg, or about 6 mg. mg, about 10mg, about 25mg, about 50mg, about 100mg, about 150mg, about 200m g, about 300 mg, about 500 mg, about 600 mg, or about 1000 mg of active ingredient possible.

[0135] The mode of administration may be by administration to the host using tablet, capsule, liquid, powder, gel, or particulate formulations. Any suitable route of delivery of the antibody, for example parenteral administration, e.g., intradermal, intramuscular, intraperitoneal It may be intravenous, subcutaneous, pulmonary, or mucosal (oral, intranasal, intravaginal, rectal), The device may be included in a cartridge, an implantable device, an osmotic pump, a cartridge, or a micropump. or other means known in the art and recognized by those of skill in the art. Parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous, or subcutaneous, pulmonary, or mucosal administration, using a By any suitable route of delivery of the antibody to the host, such as intravenous, intranasal, intravaginal, or rectal administration. Site-specific administration can be, for example, intratumoral, intraarticular, intrabronchial, intraperitoneal, intracapsular, soft tissue, or intradermal. Intraosseous, intrasinusoidal, intracavity, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intramyocardial, intraosseous, pelvic Intracellular, pericardial, abdominal, pleural, prostatic, pulmonary, rectal, renal, retinal, spinal cord, synovial fluid Intravesical, intrathoracic, intrauterine, intravascular, intrabladder, intralesional, intravaginal, intrarectal, oral, sublingual, intranasal or by transdermal delivery.

[0136] Generation of bispecific anti-EGFR / c-Met antibodies for use in the methods of the present disclosure Exemplary anti-EGFR / c-Met antibodies that can be used in the methods of the disclosure include: JNJ-372. JNJ-273 is characterized by the following amino acid sequence: EGFR binding arm >SEQ ID NO:1 (HCDR1, EGFR binding arm) TYGMH >SEQ ID NO:2 (HCDR2, EGFR binding arm) VIWDDGSYKYYGDSVKG >SEQ ID NO:3 (HCDR3, EGFR binding arm) DGITMVRGVMKDYFDY >SEQ ID NO:4 (LCDR1, EGFR binding arm) RASQDISSALV >SEQ ID NO:5 (LCDR2, EGFR binding arm) DASSLES >SEQ ID NO:6 (LCDR3, EGFR binding arm) QQFNSYPLT >SEQ ID NO:7 (HCDR1, c-Met binding arm) SYGIS >SEQ ID NO:8 (HCDR2, c-Met binding arm) WISAYNGYTNYAQKLQG >SEQ ID NO:9 (HCDR3, c-Met binding arm) DLRGTNYFDY >SEQ ID NO: 10 (LCDR1, c-Met binding arm) RASQGISNWLA >SEQ ID NO: 11 (LCDR2, c-Met binding arm) AASSLLS >SEQ ID NO: 12 (LCDR3, c-Met binding arm) QQANSFPIT >SEQ ID NO: 13 (VH, EGFR binding arm) QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQ APGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTL YLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGT LVTVSS >SEQ ID NO: 14 (VL, EGFR binding arm) AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQK PGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQ PEDFATYYCQQFNSYPLTFGGGTKVEIK >SEQ ID NO: 15 (VH, c-Met binding arm) QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQ APGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTA YMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS >SEQ ID NO: 16 (VL, c-Met binding arm) DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHK PGKAPKLLIYAASSLLSGVPSRFSGSGSGTFTLTISSLQ PEDFATYYCQQANSFPITFGQGTRLEIK >Sequence number 17 HC1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQ APGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTL YLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK >SEQ ID NO:18 LC1 AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQK PGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQ PEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC >Sequence number 19 HC2 QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQ APGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTA YMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK >Sequence number 20 LC2 DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHK PGKAPKLLIYAASSLLSGVPSRFSGSGSGTFTLTISSLQ PEDFATYYCQQANSFPITFGQGTRLEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC

[0137] Similar characteristics when compared to JNJ-372 described in U.S. Pat. No. 9,593,164 Other publicly available bispecific anti-EGFR / c-Met antibodies are not intended to be construed as limiting the scope of the present disclosure, so long as they demonstrate Bispecific anti-E that can be used in the methods of the present disclosure The GFR / c-Met antibody also contains publicly available EGFR-binding VH / VL domains and The c-Met binding VH / VL domains were combined to produce a bispecific antibody, which is disclosed in U.S. Pat. It can also be produced by testing for the characteristics described in US Pat. No. 9,593,164. Cut.

[0138] The bispecific anti-EGFR / c-Met antibodies used in the methods of the disclosure can be, for example, cell-free. Two antibody fragments with different specificities can be isolated in vitro or by co-expression in a genomic DNA environment. Substitutions were made at the heavy chain CH3 interface of each half molecule to make the molecule more likely to form heterodimers. By introducing the Fab arm exchange (or half molecule) between two monospecific bivalent antibodies, Fab arm exchange reactions can be used to generate Fab arm fragments by disulfide bond heterodimerization. The result is the activation reaction and dissociation-association of the CH3 domain. Hinge region of the parent monospecific antibody The heavy chain disulfide bonds in the parent monospecific antibody are reduced. The isolated cysteine ​​forms an intra-heavy chain disulfide bond with a cysteine ​​residue of the second parent monospecific antibody molecule. At the same time, the CH3 domain of the parent antibody is released and reformed by dissociation-association. The CH3 domain of the Fab arm appears to prefer heterodimerization over homodimerization. The resulting products may each target a different epitope, i.e., EGFR It has two Fab arms that bind to an epitope in c-Met and an epitope in c-Met. For example, the bispecific antibody of the present invention is a bispecific antibody having half molecules. The antibody can be produced using the techniques described in US Pat. No. 2011 / 131746. In the case of the antibody, the mutation F405L in one heavy chain and K409R in the other heavy chain were used. In the case of IgG2 antibodies, wild-type I with F405L and R409K substitutions can be used. IgG2 and IgG2 antibodies may be used. In IgG4 antibodies, F405L and R409 Wild-type IgG4 and IgG4 antibodies with K substitutions may be used. To achieve this, the first monospecific bivalent antibody and the second monospecific bivalent antibody are The mutant was engineered to have the aforementioned mutations, and the cysteines in the hinge region were designed to inhibit disulfide bond isomerization. The antibodies are incubated together under reducing conditions sufficient to allow the antibody to undergo Bispecific antibodies are generated by Fab arm exchange. The incubation conditions are optimally: An exemplary reducing agent that can be used is 2-mercaptoethylamine. 2-mercaptoethylamine (2-MEA), dithiothreitol (DT T), dithioerythritol (DTE), glutathione, tris(2 -Carboxyethyl)phosphine (tris(2-carboxyethyl)phosphine, TCEP), L- cysteine, and β-mercaptoethanol. For example, at a temperature of at least 20° C. , in the presence of at least 25 mM 2-MEA or at least 0.5 mM dithiothreate in the presence of ethanol at pH 5-8, e.g. pH 7.0 or pH 7.4, for at least 90 minutes. Incubation of the cells can be used.

[0139] The bispecific anti-EGFR / c-Met antibodies used in the methods of the disclosure are knob-in-hole (Genentech), CrossMAb (Roche) and electrostatic match (ele ctrostatically-matched)(Chugai,Amgen,Nov oNordisk, Oncomed), LUZ-Y (Genentech), Stran d Exchange Engineered Domain body(SEEDbo dy) (EMD Serono), and Biclonic (Merus) designs. It can also be prepared using

[0140] "Knobs-in-holes" strategies (see, e.g., WO 2006 / 028936) In the present study, the selected amino acids forming the interface of the CH3 domain of human IgG were To promote dimerization, mutations were introduced at positions that affect CH3 domain interactions. An amino acid with a small side chain (hole) specifically binds to the first antigen. An amino acid with a large side chain (knob) is introduced into the heavy chain of the antibody to bind to a second antigen. After co-expression of the two antibodies, a heterodimer is formed, called a "homologous" antibody. These are formed as a result of preferential interactions between heavy chains that have a "hole" and heavy chains that have a "knob". Exemplary CH3 substitution pairs that form the knob and hole are T366Y / F405A, T 366W / F405W, F405W / Y407A, T394W / Y407T, T394S / Y407A, T366W / T394S, F405W / T394S, and T366W / T 366S_L368A_Y407V (in the first CH3 domain of the first heavy chain (expressed as modification position / modification position in the second CH3 domain of the second heavy chain).

[0141] In addition to utilizing the "knobs-in-holes" strategy to promote Fab arm exchange, Cr The ossMAb technology utilizes a CH1 / CL domain swap in one of the half arms to obtain 2. Ensure correct light chain pairing of bispecific antibodies (see, e.g., U.S. Patent No. 8,242, (See issue 247).

[0142] Other cross-linking methods can be used to cross-link either or both of the heavy and light chains of the bispecific antibody, or within the heavy chain. By exchanging the variable or constant domains, or both, in the Full length bispecific antibodies may be produced. These exchanges include, for example, those described in International Patent Publication No. 2009 / 080254, 2009 / 080251, 2009 / 01838 VH-CH1, VL-CL, and VH-CH2 described in Patent No. 6 and Patent No. 2009 / 080252 and VL, CH3 and CL, and CH3 and CH1.

[0143] Other strategies, such as combining positively charged residues on one CH3 surface and Heavy chain heterodimerization using electrostatic interactions by replacing negatively charged residues in The promotion of somatization is described in U.S. Patent Application Publication Nos. 2010 / 0015133 and 2009 / 018 2127, 2010 / 028637, or 2011 / 0123532. In another approach, heterodimerization may be used as described in U.S. Pat. No. 2012 / 0149876 or U.S. Patent Application Publication No. 2013 / 0195849 Replaces: L351Y_F405A_Y407V / T394W, as listed T366I_K392M_T394W / F405A_Y407V, T366L_K392 M_T394W / F405A_Y407V, L351Y_Y407A / T366A_K4 09F, L351Y_Y407A / T366V_K409F, Y407A / T366A_ K409F, or T350V_L351Y_F405A_Y407V / T350V_T3 66L_K392L_T394W (modification position in the first CH3 domain of the first heavy chain / represented as a modification position in the second CH3 domain of the second heavy chain can be done.

[0144] SEEDbody technology may be utilized to generate bispecific antibodies of the invention. Dbodies are characterized in their constant domains by the peptides described in U.S. Patent Application Publication No. 2007 / 0287. As described in issue 170, the IgA residues are substituted to promote heterodimerization. The antibody has selected IgG residues.

[0145] Mutations are typically made using standard methods to introduce DNA fragments into molecules such as the constant domain of an antibody. It is done at A level.

[0146] The invention will now be described with reference to the following specific, non-limiting examples.

[0147] Materials and Methods Isolation of PBMCs, and NK cells and monocytes from PBMCs Peripheral blood mononuclear cells (PBMCs) and isolated immune cells (NK cells and monocytes) were obtained from Hemaca PBMCs were purchased from IRB-approved healthy human donors using cGMP and cG. TPs were collected at HemaCare's FDA-registered collection center in accordance with collection guidelines. Peripheral blood mononuclear cells (PBMCs) were isolated from leukopaks by density gradient centrifugation. The antibody was purified and purchased from HemaCare in a frozen format and stored in liquid nitrogen until use. Stored inside.

[0148] For some donors, PBMC, NK cells, and The leukopak was divided into three groups to isolate monocytes and CD56 negative selection was used. NK cells were isolated and isolated using CD14 negative selection. The isolated NK cells and monocytes were , purchased from HemaCare in a cryopreserved format and stored in liquid nitrogen until use. did.

[0149] Differentiation of monocytes into M1, M2a, and M2c macrophages Monocytes (purchased from Hemacare) were cultured in XVIVO 15 medium supplemented with 10% FBS. The cells were thawed at room temperature and plated into tissue culture treated T75 flasks. On day 0, monocytes 50ng / mL M-CSF (Cat. No. 216-MC-025 / CF, R&D s Mo macrophages were obtained by plating in a medium containing 100% glycerol (purchased from Immune Systems). To polarize M0 macrophages to M2a macrophages, on day 5, the medium was 0 ng / mL M-CSF and 20 ng / mL IL-4 (Cat. No. 204-IL-4) 020 / CF, purchased from R&D systems) and 20 ng / mL IL-13 (CaCl Catalog number 213-ILB-025 / CF, purchased from R&D systems) The M0 macrophages were polarized to M2c macrophages and incubated for 48 hours. On day 5, the medium was supplemented with 50 ng / mL M-CSF and 20 ng / mL IL-1. 10 (catalog number 217-IL-025 / CF, purchased from R&D systems) and The medium was replaced with a new one and incubated for 48 hours. The medium was diluted with 50 ng / mL M-CSF and 100 ng / mL IFN-g (Cat. No. 28 5-IF-100 / CF, purchased from R&D systems) and used for 24-hour ink transfer. Polarized M1, M2a, and M2c macrophages were then incubated with Accu The cells were removed from the flask using tase and used in the assay.

[0150] Depletion of NK cells and monocytes from PBMCs EasySep Human CD from STEMCELL Technologies 56 Positive Selection kit II (Cat. No. 17855 NK cell depletion was performed using 100% erythrocyte sedimentation (100% NK cell depletion medium) from STEMCell Technologies. EasySep Human CD14 Positive Selection Monocyte depletion was performed using it II (cat. no. 17858). (purchased from Hemacare) were thawed in X-VIVO-15 medium containing 10% FBS. PBMCs (10 million cells per depletion) were diluted to the desired concentration of 100 million cells / mL. NK cell and monocyte depletion was performed according to the manufacturer's protocol. The protocol was followed. Briefly, 50 μl of each antibody selection cocktail was added. The magnetic particles were vortexed for 30 seconds and 50 μl of was added to the PBMC + antibody cocktail. This was incubated at room temperature for 3 minutes and then incubated with Easy The tube was then filled to 2.5 mL with Sep buffer. net (catalog number 18000, manufactured by STEMCell Technologies) The supernatant was then carefully transferred to a new tube. The separation step was repeated twice to obtain NK cell-depleted and monocyte-depleted PBMCs. Flow cytometry (as described below) was used to confirm depletion, and then These PBMCs were used in a Simple Western assay to detect EGFR and M et protein levels were detected.

[0151] Determination of immune cell composition within PBMCs PBMCs (purchased from Hemacare) were cultured in X-VIVO-15 containing 10% FBS. After counting, approximately 300,000 to 400,000 cells / well were plated. Plates were spun at 1500 rpm for 3 minutes at 4°C. The supernatant was discarded and the cells were washed with 150 μl / well of DPBS. Spin again as above and pellet. Add 150 μl of DMSO to the contents of the live / dead stain. By adding to Near IR-Live / Dead stain(Life A stock solution of 1000 mg ... Working solution was prepared by adding 50 μl of stock to 10 mL of DPBS. Next, 50 μL of the working solution was added to each well of the plate and resuspended. The plate was incubated in the dark (covered in foil) for 30 minutes at room temperature. At the end of incubation, the plate was spun for 5 minutes at 4° C. and 1500 rpm. Cells were stained with FACS / Stain buffer (B D No. 554657) buffer. For multicolor flow cytometry panels of antibodies were prepared into cocktails according to calculations and added at 25 μl / well. The antibodies used were CD19 (FITC), CD56 (BV711), and Cd11b (BUV39 5), CD14 (PE-cy7), CD3 (BV605), CD4 (BV785), CD 8 (PerCP-cy5.5), CD25 (PE), and PD-1 (APC). The plate was incubated in the dark at room temperature for 30 minutes. Compensation was performed according to calculations. Compensation plate was performed using the fusion beads and single channel antibodies from the above panel. The plates were prepared and incubated in the dark at room temperature for 30 minutes. All plates were incubated at 4°C. The cells were spun at 1500 rpm for 5 minutes and washed twice with 150 μl of FACS buffer. The safety plate was placed in 150 μl of FACS buffer, and the compensation plate was placed in 20 The plates were run on a Fortessa and resuspended in 100 uL of FACS buffer. Compensation was set using single channel control values ​​from the compensation bead plate. The assay plate was then run at a flow rate of 1.5 μl / sec with compensation applied. Export the data, analyze it in FLOWJo, and perform appropriate gating to identify PB The percentage of each of the individual immune cell populations within MCs was obtained.

[0152] Proliferation and apoptosis assays HCI-H1975 cells (also referred to herein as H1975 cells) were purchased from ATCC Obtained and supplemented with 10% Hi FBS, 1x NEAA, and 1x sodium pyruvate. The mice were cultured in PMI (Invitrogen, Catalog No. 72400-047). For proliferation and apoptosis assays using cucyte, H1975 cells were incubated with 100 μg / ml of cucyte. cyte NucLight Red Lentiviral Reagent (Cat. No. 4476, Es Sen Biosciences) and selected with 1 μg / ml puromycin. These cells were cultured at 10 RPMI-Fermented with 100% HI FBS, 1x NEAA, and 1x sodium pyruvate The cells were plated on Nol Red-free medium.

[0153] H1975-NucRed cells were cultured using Invitrogen Cell Dissociation tion Buffer (for trypsin to degrade cell surface receptors / molecules) The cells were dissociated and counted. The cells were centrifuged at 1200 rpm for 5 minutes and the supernatant was removed. The pellet was resuspended in an appropriate volume of phenol red-free medium at 20°C. Cells (target cells) were plated in 100 μl of phenol red in tissue culture treated black flat bottom plates. Plate 12,500 cells / well in 100% NaCl medium and incubate at 37°C and 5% CO overnight. The next day, PBMCs ( The PBMCs were thawed and counted at 125,000 in 50 μl. The cells were diluted to a concentration of 10:1 cells / well to obtain an effector:target (E:T) ratio of 10:1. ucyte Annexin V Green reagent (catalog number 4642, Essen (purchased from Biosciences) was resuspended in 100 μl of medium and was used to stain one 96-well plate. The diluted annexin reagent was added to PB 50 ul of PBMC / medium (containing annexin) was added to the assay plate. Therapeutic antibodies were then serially diluted 1:5 and added to the appropriate wells according to the calculations. Prepare a 4x concentration of antibody by adding 50 μl of the desired antibody to the appropriate wells of the assay plate. The assay plate was then placed into the appropriate slot in an Incucyte S3. The plate was equilibrated in Incucyte for 20 min before scanning. Scan every 4 hours for up to 120 hours at 100x cell / scan to measure target cell proliferation and apoptosis. The fluorescence of target cells (NucRed) and annexin (Green) were measured over time. Fluorescence of total NucRed H1 was quantified using a process definition to indicate proliferation of target cells. The total Gree area (μm2 / well) was calculated, indicating apoptosis of the target cells. The NucRed H1975 area (um2 / well) was also calculated. From this analysis, Gr Area under the curve (AUC) was calculated using aphpad Prism to measure nonlinear dose-response curves. Created a line.

[0154] For detecting EGFR, c-Met, pEGFR, and pMet protein levels Simple Western H1975 and SNU-5 cells were obtained from ATCC and stored in 10% Hi FBS, 1 RPMI supplemented with 1× NEAA and 1× sodium pyruvate (Invitrogen, The cells were cultured in a 100% ethanol-free medium (catalog number 72400-047). Dissociate H1975 cells using Buffer and transfer each cell suspension to a 50 mL conical culture. In the assay using SNU-5 (suspension cell line), the cell suspension was The cells were transferred to a 50 mL conical tube and counted. The target cells were pelleted for 5 minutes and resuspended in an appropriate volume of RPMI medium. Plate into 6-well plates at a concentration of 1,000 cells / well and incubate overnight. The next day, PBMCs (HemeCardi PBMCs were diluted to 1,000,000 cells / well. The NK cells, monocytes, or macrophages were plated at a concentration of 1:1 to obtain an E:T ratio of 10:1. If individual immune cells such as phages were used, these were diluted and incubated at 500,000 cells / The wells were plated at a concentration of 1:1 to give an E:T ratio of 5:1. Prepare therapeutic antibodies at x concentration and add 1.5 mL of desired antibody to appropriate wells of assay plate. Plates were incubated for 48 hours (for most assays) or at various time points. I bet.

[0155] At the end of the incubation period, add 100 μl of freshly prepared lysis buffer to each well. The mixture was added to 10 mL of RIPA buffer (Thermo Fisher Scientific) and incubated on ice for 5 minutes. moFisher; Catalog No. 89901) with one tablet of the phosphatase inhibitor Phosphatase inhibitor STOP (Sigma; Catalog No. 4906837001) and one tablet of protease inhibitor cOmplete™ Mini, EDTA-free protease inhibitor cocktail ( Sigma; Catalog No. 04693159001) to prepare the lysis buffer. Using a plate scraper, transfer the lysate to a 2 mL Eppendorf tube. The lysates were incubated on ice for 30 min with occasional vortexing at 4°C. The mixture was centrifuged at 13,200 rpm for 25 minutes and the supernatant was transferred to a new tube. The Pierce BCA Protein Assay Kit (catalog no. 11111111) was used according to the protocol of the Protein analysis of the lysate was performed using the log number 23227 obtained from ThermoFisher. The protein concentration was determined. Standard Pre-Diluted Standard (Cat. No. 23208, ThermoFix (obtained from Sher) was used to generate a standard curve for the assay. Prediluted standards were added in triplicate and 25 μl of sample (1:5 dilution) was added to a 96 well plate. The prepared BCA working reagent was added to one well of a flat-bottom plate in duplicate. 200 ul was added per well. The plate was gently mixed on a plate shaker for 1 minute. The plates were covered with foil and incubated at 37°C for 30 minutes. After cooling at room temperature for 5 min, the samples were analyzed using a SpectraMAX spectrophotometer at 562 nm. Protein quantification was measured.

[0156] To perform capillary-based electrophoresis using PeggySue, Anti-rabbit detection module (catalog no. D) was also purchased from Protein Simple. M-001) and anti-mouse secondary antibody (Cat. No. 042-205) were used. 0kDa Peggy Sue Separation Module (Cat. No. SM- S001, purchased from Protein Simple) was used alone. Prepare the samples and reagents and perform capillary-based electrophoresis according to the manufacturer's protocol. Briefly, two standard Pak components were used to generate a biotinylated ladder and A 5x master mix was prepared. Protein lysates were analyzed using the BCA protein assay. The concentration was adjusted to 0.25 mg / mL using 0.1x sample buffer according to the calculations using the values ​​from the previous section. Four parts of the prepared lysate were diluted with one part 5x Fluorescent Master The final concentration of the sample and biotinylated adder (a The DNA was denatured at 95°C for 5 minutes using a PCR thermocycler. The primary antibodies utilized were diluted in antibody diluent as follows: EGFR (catalog no. 2646, manufactured by Cell Signaling Technologies), 1:50; pEGFR (catalog number AF1095, R&D Systems), 1:50;c- Met (Cat. No. 3148, Cell Signaling Technology es), 1:50; pMet (Cat. No. 3077, Cell Signaling Technologies), 1:50, and loading control actin (Catalog No. 4970, Cell Signaling Technologies), 1:2 00 or (Cat. No. 4947, Cell Signaling Technology ies), 1:100. Ladder, sample, primary and secondary antibodies, separation and stacking matrix The samples were then transferred to a 384-well Peggy Sue plate according to the plate layout. The plate was spun at 2500 rpm for 5 minutes at RT and then loaded into the machine. The data were analyzed using Compass for SW software. Determine the peaks based on the molecular weight of the protein, and The area under the curve (AUC) was then calculated for the density measurements of the protein of interest. Each of the samples was normalized to the loading control actin and then compared against the untreated control. Relative changes due to treatment were obtained by normalization to control.

[0157] Confocal imaging trogocytosis assay Collect differentiated macrophages and incubate overnight at 1,00,000 cells / well (Perkin -Elmer; Catalog No. 6055302) with CellCarrier 96 Ultraplate Assays were performed using both adherent and non-adherent target cells. In the assay with adherent target cells, H1975 NucLight Red cells were Cells were plated at 20,000 / well and allowed to attach for 4 hours, then incubated at 4° C. for 1 hour. In assays using non-adherent target cells, only target cells were treated with the labeled Ab cocktail. All live imaging studies were stained with AF647-conjugated JNJ-372 or control Ab. The antibody cocktail was anti-CD11b (BD Pharm ingen; catalog no. 557701), anti-CD14 (BD Pharmingen; Catalog No. 562689), and 1:8000 Hoechst33342 (Biot The microscope consisted of a 60x water immersion objective. The Perkin-Elmer Phenix Opera will display images at 11-minute intervals. were obtained and analyzed using Columbus.

[0158] ADCC assay supplemented with 10% heat-inactivated FBS (GIBCO, Cat. No. 16140) VI PB one day prior to the assay in VO 10 medium (Lonza, catalog no. 04-380Q). Thaw the MCs and incubate them under standard incubation conditions (37°C, 5% CO2, 95% humidity). On the day of the assay, NCI-H1975 target cells were incubated with DELFIA BATD Reagent A (PerkinElmer Inc., Catalog No. C136-100) for 30 min. The PBMCs and BATDA were loaded for 10 min, washed three times, and resuspended in RPMI medium. The transfected target cells were incubated with increasing concentrations of the test antibody at an effector to target cell ratio of 25. The cells were added to a 96-well U-bottom plate at a ratio of 1:1 in RPMI medium or 2% Triton X-1. RPMI medium containing 00 (EMD Millipore, Cat. No. 648463) The medium was added to control wells for measurement of spontaneous and maximum TDA release, respectively. After incubation for 2 hours, 20 uL of the supernatant was removed and added to 200 μl of DELPHI A Europium solution (Perkin Elmer, Catalog No. C135-100 After 15 min incubation at RT, EnVision 2104 M Ultralabel Plate Reader (PerkinElmer, Catalog No. The relative fluorescence units (RFU) were measured using a fluorometer (No. 2104-0010). The lysis rate was calculated as follows: The calculation was made as follows: experimental release - spontaneous release) / (maximum release - spontaneous release) x 100.

[0159] Differentiation of monocytes into M1, M2a, and M2c macrophages Monocytes (Hemacare) were thawed in XVIVO-15 medium and incubated with 50 ng / mL of MCs. SF (R&D systems; Catalog No. 216-MC-025 / CF) for 6 days To obtain M0 macrophages, on the 5th day, M 0 macrophages were treated with 50 ng / mL M-CSF and 100 ng / mL IFN-γ (R Polarized for 48 hours in a 300-mL 300-mL incubator (&D systems; Catalog No. 285-IF-100 / CF). To obtain M2 macrophages, M0 macrophages were cultured on the 5th day and then transferred to M2a macrophages. For the IL-4 antibody, 20ng / mL IL-4 (R&D systems; Catalog No. 204-IL -020 / CF) and IL-13 (R&D systems; catalog number 213-IL B-025 / CF) or M2c macrophages, 20ng / mL IL-10 (R&D systems; Catalog No. 217-IL-025 / CF) for 48 hours. It was transformed into this.

[0160] In vivo testing 6-8 week-old female BALB / c nude mice (CAnN.Cg-Foxn1 nu / crl , Charles River Laboratories(Wilmington,M. A) H1975 cell line was subcutaneously implanted in mice. The tumor size was 72±8.7 mm on average. 3 When it becomes , starting 5 days before the start of compound administration to promote macrophage depletion and continuing for the duration of the study. Anti-mCSF-1R antibody (400 μg / mouse) was intraperitoneally administered three times a week for 5 days. Eyes (mean tumor volume = 102 ± 36.6 mm 3 ) with 10mg / kg isotype control Ab , JNJ-372, or EGFR / cMet IgG2σ Ab administered intraperitoneally weekly Tumors were sampled and macrophage infiltration was monitored after two doses of compound. In the SNU5 tumor model study, 7-8 week old female CB17 / SCID mice were (HFK Bio-Technology Co.Ltd.(Beijing,Chi SNU5 cells were subcutaneously implanted in mice. The tumors grew to an average of 155±21.4 mm. 3 It became Mice were then treated with phosphate-buffered saline (PBS), JNJ-372 (5 mg / kg), or The patients were treated with EGFR-cMet IgG2σ antibody (5 mg / kg) intraperitoneally twice weekly for 3 weeks. For both studies, tumor measurements and body weights were recorded twice weekly. Calculation [1-(T / C)] × 100 was used to measure tumor size on the last day that >80% of control mice remained on the study. Tumor growth inhibition (TGI) was calculated. All in vivo experiments were performed according to the method described by Johnson and J ohnson Institutional Animal Care and Use Committee and the Guide for Care and Use f Performed in accordance with Laboratory Animals.

[0161] Flow cytometry-based determination of tumor-associated macrophages Tumors were excised from the mice, weighed, cut into 2-4 mm sections, and resuspended in 2.5 mL of RPMI. Into a C-tube (Miltenyi, catalog number 130-093-237) containing The cells were then placed in a 50-mL syringe and kept on ice. citation kit (Miltenyi, catalog number 130-095-929) Reconstitute the lyophilized enzymes contained in the kit to prepare a 2x enzyme cocktail, as described in the manufacturing protocol "h GentleMACS Octo Dissociato using "_tumor_01" The tumors were dissociated using 100% ethanol (Miltenyi, Cat. No. 130-095-937) followed by The dissociated cells were then subjected to FACS analysis. Stain Buffer (BD Pharmingen, Catalog No. 554657) The cells were washed twice with 500 mL of 10 ... Cells were then passed through a 1:1000 dilution of Gol Incubate in giPlug (BD, Cat. No. 555029) at 37°C for 3 hours. The cells were incubated for 1 h, washed twice, and resuspended in 100 μL of antibody staining cocktail. The cocktail consisted of anti-CD45 (Cat. No. 103138), anti-F4 / 80 (Cat. No. 1 23137), anti-Ly6G (Cat. no. 127639), anti-MHCII (Cat. no. 107612), anti-EpCAM (Cat. No. 324214), anti-PD1 (Cat. No. 135231), anti-PD-L1 (Cat. No. 393606), anti-CD206 (Cat. No. No. 141729) (BioLegend), anti-CD11b (Cat. No. 56355 3) and anti-Ly6C (catalog no. 561237) (Becton-Dickinson (Cat. No. 25-5920-82), anti-iNOS (Cat. No. 25-5920-82) and Fixable Live / Dead stain (Cat. No. L10119) (Invitrogen) The cells were incubated with external cell surface marker antibodies for 30 min at 4°C protected from light. Incubate, wash twice with PBS, and then add Fixable Live / Dead stain. The cells were resuspended in PBS containing in and incubated at 4°C for 30 min and then washed with FACS buffer. The samples were washed twice with BD Pharmingen (cat. no. 554657). Cells were fixed / permeabilized according to the manufacturer's instructions (Invitrogen, Cat. No. 88- 8824-00), incubated with internal target antibody for 30 minutes at 4°C, and FACS buffered. Wash twice with PBS and resuspend in 200 μL for analysis on the BD LSR Fortessa. UltraComp Beads (for antibodies; Invitrogen, Catalytic Log No. 01-2222-42) and ArC Amine Reactive Beads (F For ixable Live / Dead; Invitrogen, Catalog No. A10 Correction was performed using the FMO standard deviation (FMO) control for all markers. To assess macrophage depletion, macrophages were cultured using CD45 + CD11b + Ly 6C - Ly6G - F4 / 80 + was defined as:

[0162] MSD multiplex assays and statistical analysis For PBMC, NK cell, and monocyte experiments, NCI-H1975 cells were plated in 96-well plates. The plates were plated and incubated overnight at 37°C and 5% CO2. PBMCs, monocytes, or NK cells were added at ratios of 10:1, 5:1, and 5:1, respectively. For macrophage experiments, monocytes were differentiated as previously described and incubated with StemPro A. The cells were dissociated using cutase (Gibco, Cat. No. A11105-01) and then 9 Plated in 6-well plates and incubated overnight at 37°C and 5% CO2 The next day, NCI-H1975 cells were added at an E:T ratio of 5:1. Cells were treated with type control, JNJ-61186372, or IgG2 Sigma and incubated at 37°C and The plates were incubated at 5% CO2 for 4, 24, 48, and / or 72 hours. At the designated times, the plate was spun at 1200 rpm for 10 minutes at room temperature. The supernatant was removed and the preparation MesoScale was used for each cytokine assay according to the manufacturer's instructions. Using Discovery (MSD) U-plex and V-plex formats Briefly, U-plex plates were prepared the day before the assay. Plates were coated with antibodies and linkers according to the manufacturer's protocol and incubated overnight at 4°C. On the day of the experiment, U-plex or V-plex plates were incubated on a thermal shaker. The plate was washed three times with MSD wash buffer and the supernatant was added to the plate, and standards and calibrators were added. The plates were read on an MSD Sector instrument. The standard curves were used to analyze each cytochrome P450 / cytochrome P450 sb protein. Calculated levels (pg / ml) of leukemia virus were obtained.

[0163] From the calculated concentrations, the magnitude of the response was compared for each treatment, cell type, and incubation period. The area under the curve (AUC) was calculated by the trapezoidal method for each incubation time. If below the lower limit of detection, exclude response data and include at least 6 valid responses across 8 dose levels. AUC was calculated only if there were any significant observations. Availability of data (no data, insufficient data, or not calculable) across all conditions and A heat map was then created to show the AUC data (Figure 1). Create a heatmap of log-transformed AUC by application time and use H197 For cytokines with at least one measurable AUC in 5+ PBMC cell types All heat maps were generated using the statistical software R version 3.5.0. Created using the R package (R Core Team 2018; R :A language and environment for statistics cal computing;http: / / www.R-project.org / ) Finally, the relative changes of JNJ-372 and IgG2σ treatment compared to the isotype were examined under each condition. The data were calculated using the following formula and bar graphs or dose curves were generated using Graphpad Prism. .

[0164] Example 1. JNJ-372-mediated anti-proliferative and apoptotic effects on tumor cells is driven by Fc interactions with immune cells To evaluate the effect of Fc interactions on the three antitumor mechanisms of JNJ-372, Using standard cloning methods, Fc effector silent IgG2 sigma (wild type Compared to IgG2, V234A G237A P238S H268A V309L A IgG2 containing the 330S P331S mutation (Sigma) replaces JNJ-372 wild-type IgG1 We engineered JNJ-372 to be an Fc effector-silent molecule by converting (JNJ-372.IgG2 Sigma). The antibody was designated JNJ-372.IgG2 sigma (or IgG2s in some figures). JNJ-372 enhances binding to FcγRIII / CD16 and ADCC. , produced in cell lines incorporating low concentrations (<9%) of fucose. As a result, JNJ-372 was expressed in CHO cells that had normal fucose levels. This molecule is called JNJ-372.NF (NF: normal fucose). Tumor cell killing assessed using H1975 cells (ATCC Catalog No. CRL-5908) The cell line expresses mutant L858R / T790M EGFR and wild-type c-Met. do.

[0165] NCI-H1975 NucLight Red expressing cells were used as isotype control, JNJ Treatment with JNJ-372, JNJ-372.IgG2s, or JNJ-372.NF at 10:1 After initiation of co-culture, the cells were cultured in the presence or absence of PBMCs at an effector:target ratio of Proliferation of NCI-H1975 cells was assessed over a 5-day period. The presence of PBMCs was associated with a dose-dependent increase in Although JNJ-372 potentiated the ability of the antibody to inhibit tumor cell proliferation over time, NJ-372 did not inhibit proliferation in the absence of PBMCs at the concentrations tested ( Figure 2).

[0166] To confirm that Fc engagement on PBMCs is responsible for the effect, H1975 NucLight Red expressing cells were JNJ-372, JNJ-372.IgG2 Sigma and JNJ-372.NF, and were incubated in the presence or absence of PBMCs at an E:T ratio of 10:1. The cells were cultured in the presence of 500 mg / mL ... The presence of PBMCs was assessed at 24, 48, 72, and 96 hours. Dose-dependent antiproliferative effect and dose-dependent apoptosis induced by JNJ-372 (A The results were enriched for isotype or JNJ-372.IgG2 signaling. No or minimal effects were observed in PBM after 72 hours of culture. Isotype control, JNJ-372, JNJ-372 in the presence or absence of C Inhibition of H1975 cell proliferation mediated by IgG2 Sigma or JNJ-372 NF FIG. 4 shows the dose response in the presence or absence of PBMC after 48 hours of culture. , isotype control, JNJ-372, JNJ-372.IgG2 Sigma, or JNJ- 3 shows the dose response of 372.NF-mediated apoptosis. Partial effect on proliferation (Fig. 3) and apoptosis (Fig. 4) when compared with NJ-372 This is because FcγRIII plays a role, but it is not a mediator of Fc interactions. This suggests that this does not fully explain the effect of intervention.

[0167] The assay consisted of PBMCs from seven different donors at an effector:target ratio of 10:1. IC in the NCI-H1975 proliferation assay for six donors. 50 Values ​​and % maximum killing are shown in Table 1. PBMC from one donor had no effect. Across PBMCs obtained from different donors, IC 50 and variation in maximum kill percentage The phenomenon was observed.

[0168] [Table 1]

[0169] Example 2. EGFR and c-Met Proteins in EGFR Mutant Tumor Cell Lines and JNJ-372-mediated downregulation of these downstream signaling pathways Mediated by Fc interactions with immune cells The presence of immune cells (PBMCs) was associated with the expression of EGFR and c-Met proteins in JNJ-372 mediated downregulation as well as inhibition of their phosphorylation.

[0170] NCI-H1975 cells were treated with 10 μg / mL isotype or JNJ-372. 4, 2 at an E:T ratio of 10:1 in the presence or absence of PBMC from one donor After incubation for 4, 48, or 72 hours, EGFR, c-Met, and pEGFR(pY1173 Actin was used as a loading control. At all time points tested, EGFR, c-Met, and pEGFR(pY117 3) enhanced JNJ-372-mediated downregulation of As shown, mice were treated with isotype control or JNJ-372 and cultured in the presence or absence of PBMCs. Capsules showing EGFR and c-Met proteins and pEGFR in samples cultured with Array-based electrophoresis (Simple Western with PeggySue) Figure 6 shows the relative amount of EGFR in each sample. Figure 7 shows the relative amount of pE Figure 8 shows the relative amount of c-Met in each sample. Samples were normalized to the amount of loading control actin present in each sample and then and normalized to control (untreated) samples.

[0171] PBMCs from seven donors were analyzed for EGFR and c-Met protein levels and pE The ability to enhance JNJ-372-mediated inhibition of GFR was tested. Donor PB Variability was observed between MCs. PBMCs from donors 1, 3, 4, and 6 were JNJ- 372 was the most potent mediated effect enhancer. Figure 9 shows the results of 7 Isotype control or EGFR and c-Met proteins and pEGFR in samples treated with JNJ-372 Capillary-based electrophoresis (Simple We stern) are shown. Figure 10 shows the relative amount of EGFR in each sample. The relative amount of pEGFR pY1173 in each sample is shown in FIG. The relative amounts of -Met are shown. Samples were weighted according to the amount of loading control actin present in each sample. The results were normalized to the control (untreated) sample.

[0172] Example 3. Presence of monocytes or macrophages influences EGFR and c-Met signaling is sufficient and necessary for Fc-mediated enhancement of the inhibitory effect of JNJ-372 against JNJ-372 downregulates EGFR and c-Met signaling To understand the variability in the ability of different PBMC samples to enhance Using flow cytometry, PBMCs from the seven different donors used in Example 2 were We assessed the immune cell composition of the donors. The distribution of individual immune cells in each of the seven donors was and each donor PB mediated downregulation of EGFR / pEGFR / Met Correlation was performed with the ability of MC. NK cells, B cells, or T cells and EGFR, pEGFR No correlation was observed between the ability of PBMCs to down-modulate c-Met or to down-modulate c-Met. However, the % of monocytes in PBMCs and the EGFR tandem and the ability of PBMCs to enhance down-modulation of protein levels (Figure 13). Correlation between % monocytes in BMCs and ability of PBMCs to enhance pEGFR down-modulation (Figure 14), and down-modulation of monocyte percentage and c-Met protein levels in PBMCs. A positive correlation was identified between the ability of PBMCs to enhance cellular proliferation and proliferation (Figure 15). JNJ-372-mediated signal downregulation in PBMCs These results suggest that a higher monocyte rate is needed.

[0173] PBMCs from a single donor were depleted of NK cells or monocytes and were then subjected to EGFR and c-Me NK or monocyte depletion for JNJ-372-mediated down-modulation of the t pathway The effect of PBMC was evaluated. H1975 cells were treated with 10 μg / mL isotype control or JN NK cell-depleted PBMC or monocyte-depleted PBMC obtained from one donor treated with J-372 The cells were cultured for 48 h at an E:T ratio of 10:1 in the presence or absence of MC. Consistent with these results, the presence of PBMCs significantly increased the expression of EGFR, pEGFR, and EGFR-associated ... and enhanced JNJ-372-mediated downregulation of c-Met. Depletion of monocytes from PBMCs had only a small effect, but depletion of monocytes from PBMCs Ability of PBMCs to enhance JNJ-372-mediated signal down-modulation Figure 16 shows that the force was significantly restored in the presence of JNJ-372 or isotype control as shown in the figure. Presence of NK cell-depleted PBMC or monocyte (mono)-depleted PBMC from one donor EGFR, c-Met, and EGFR expression in NCI-H1975 cells cultured for 48 hours in the presence or absence of EGFR. and capillary-based electrophoresis (Pegg) to detect pEGFR protein levels. Figure 17 shows images from a Simple Western run using ySue. As described above, NK cell depletion from one donor was performed using treatment with JNJ-372 or isotype control. NCs cultured for 48 h in the presence or absence of depleted or monocyte (mono)-depleted PBMCs Figure 18 shows the relative amount of EGFR in JNJ-372 I-H1975 as indicated. or isotype control, and NK cell-depleted PBMC or monocytes (monocytes) from one donor were treated with pE in NCI-H1975 cells cultured for 48 hours in the presence or absence of depleted PBMCs Figure 19 shows the relative amount of GFR (pY1173). Treated with isotype control and NK cell-depleted PBMC or monocytes (mono) from one donor c-Me in NCI-H1975 cells cultured for 48 h in the presence or absence of depleted PBMCs The relative amounts of actin present in each sample are shown. Normalization was then performed against the control (untreated) sample.

[0174] To further evaluate the role of the myeloid compartment, we investigated the JNJ-372 Fc interaction. One PBM for EGFR / c-Met downregulation driven by The effect of monocytes or M1 macrophages isolated from C donors was evaluated. To assess the differential effects, monocytes were differentiated in two ways using M-CSF and GM-CSF. M1 macrophages were obtained by inducing H1975 cells with 10 μg / mL Isotype, JNJ-372, JNJ-372.IgG2 Sigma treated, 10:1 (P BMC) or 5:1 (individual immune cells (monocytes, NK cells, MCSF M1, or G MCSF M1 macrophages) and the presence of PBMC from one donor. The PBMCs were cultured for 48 hours in the presence or absence of EGFR, pEGFR , and enhanced JNJ-372-mediated downregulation of c-Met protein. NK cells had no significant effect, but were isolated from the same PBMC donor. Monocytes or M1 macrophages (differentiated by M-CSF or GM-CSF) were The effect of -372 on signal downmodulation was significantly enhanced. , myeloid lineage, Fc interactions, and JNJ-372 signaling downregulation These results suggest that the PBMC-mediated enhancement of IL-1 expression in the IL-1 / IL-2 mice is sufficient for PBMC-mediated enhancement of IL-1 / IL-2 in the mice. As shown, PBMCs, isolated monocytes, isolated NK cells, and MCSF-differentiated M1 macrophages from the same donor were for 48 h in the presence or absence of rHA or GMCSF-differentiated M1 macrophages. EGFR in NCI-H1975 cells treated with JNJ-372 or isotype control; Capillary-based electrophoresis to detect c-Met and pEGFR protein levels Images from the experiment (Simple Western with PeggySue) are shown in Figure 2. 1 shows the results of PBMC, NK cells, monocytes, and MCSF M1 cells isolated from the same donor as indicated. 48 hours in the presence or absence of macrophages or GMCSF M1 macrophages , JNJ-372, JNJ-372.IgG2 Sigma, or isotype control. Figure 22 shows the relative amount of EGFR in NCI-H1975 cells. PBMCs, NK cells, monocytes, MCSF M1 macrophages, or GM cells isolated from donors In the presence or absence of CSF M1 macrophages for 48 h, JNJ-372, JNJ -372. In NCI-H1975 cells treated with IgG2 Sigma or isotype control Figure 23 shows the relative amounts of pEGFR(pY1173) from the same donor as shown in the figure. PBMCs, NK cells, monocytes, MCSF M1 macrophages, or GMCSF isolated from JNJ-372, JNJ-37 in the presence or absence of M1 macrophages for 48 hours 2. c- in NCI-H1975 cells treated with IgG2 sigma or isotype control The relative amounts of Met are shown. Samples were compared against the amount of loading control actin present in each sample. were normalized to 0.01 and then normalized to the control (untreated) sample.

[0175] Subsequently, EGFR / c-Met downregulation was driven by JNJ-372 Fc interaction. We assessed the effect of different macrophage subtypes on oncogenesis. Donor-derived monocytes were differentiated into M1, M2a, and M2c macrophages and were then cultured with JNJ-37 The ability of IL-2 to enhance EGFR / c-Met downmodulation mediated by IL-2 was evaluated. H1975 cells were incubated with 10 μg / mL of isotype control, JNJ-372, Obtained by differentiation of monocytes from one donor using IgG2 Sigma treatment. In the presence or absence of M1, M2a, and M2c macrophages, the E: The presence of M1, M2a, and M2c was all associated with EGFR, pEGF R, and JNJ-372-mediated downregulation of c-Met protein. As shown in FIG. 24, JNJ-372, JNJ-372.IgG2 Treatment with sigma or isotype control resulted in M1 macrophages (M1) or M2a macrophages (M2a). EGFR, c-Me in NCI-H1975 cells cultured in the presence of phage (M2a) Capillary-based electrophoresis (Pe Figure 25 shows images from a Simple Western scan using ggySue. As indicated, JNJ-372, JNJ-372.IgG2 Sigma, or isotype control and cultured for 48 h in the presence or absence of M2c macrophages (M2c Detecting EGFR, c-Met, and pEGFR levels in CI-H1975 cells Capillary-based electrophoresis (Simple Western with PeggySue) ) images are shown.

[0176] Example 4. EGFR and c-Met proteins and their downstream signaling pathways J-372-mediated downregulation of c-Met expression in c-Met-amplified tumor cell lines Mediated by Fc interactions SNU-5 cells (c-Met amplified cell line) were incubated with 10 μg / mL JNJ-372 or In the presence or absence of PBMCs from one donor, treated with isotype control, The cells were cultured for 48 hours at an E:T ratio of 10:1. The addition of PBMCs was performed to confirm that JNJ-372 inhibits EGFR , enhanced ability to downregulate pEGFR, c-Met, and p-Met Figure 26 shows the results of PBMCs treated with JNJ-372 or isotype control as indicated. EGFR, c-Met, and pEGFR in SNU-5 cells cultured in the presence or absence of Capillary-based electrophoresis (PeggySue) to detect FR protein levels Figure 27 shows images from a Simple Western microscope (SWS) using the J Treated with NJ-372 or isotype control and cultured in the presence or absence of PBMCs Figure 28 shows the relative amount of EGFR in SNU-5 cells. SNU-5 cells were treated with IgG or isotype control and cultured in the presence or absence of PBMCs. Figure 29 shows the relative amount of pEGFR(pY1173) in the cells. SN cultured for 48 h in the presence or absence of 372, isotype control, or PBMCs Figure 30 shows the relative amount of c-Met in U-5 cell culture samples. SNU treated with 372 or isotype control and cultured in the presence or absence of PBMCs The relative amounts of pMet (pY1234 / 1235) in -5 cells are shown. Normalize to the amount of loading control actin present and then compare it with the control (untreated) sample. Normalized against .

[0177] Example 5. JNJ-372 and FcγR-mediated tumor growth inhibition in vivo Fc interaction Next, the Fc / FcγR phase was examined using H1975 and SNU5 cell line xenograft models. The role and relevance of the interactions were evaluated in vivo.

[0178] 6-8 week-old female BALB / c nude mice (CAnN.Cg-Foxn1 nu / crl , Charles River Laboratories(Wilmington,M. A) NCI-H1975 cell line was subcutaneously implanted in mice. The tumor size was 72±8.7 mm on average. 3 Nina When the mice were treated with 100 mg / kg / day ... Anti-mCSF-1R antibody (400 μg / mouse) was administered intraperitoneally three times a week for the duration of the study. On the fifth day, the tumor size was an average of 102 ± 36.6 mm 3 When the α-amino acid concentration reached 1.0, the isotype control Ab ( 10mg / kg), JNJ-372(10mg / kg), or JNJ-372.IgG2 The mice were treated with Sigma (10 mg / kg) intraperitoneally twice a week. Tumors were sampled to monitor macrophage infiltration after two doses of compound. 7-8 week-old female CB17 / SCID mice (HFK Bio-Technology The SNU5 cell line was subcutaneously transplanted into the tumor tissue of a mouse model animal (Headquarters: Tokyo, Japan). Average tumor size: 155±21.4mm 3 When the mice reached 100 mg / kg, they were placed in phosphate buffered saline (PBMS) S), JNJ-372 (5 mg / kg), or JNJ-372.IgG2 Sigma (5 mg Each subject was treated intraperitoneally with 0.01 mg / kg twice weekly for three weeks. Tumor measurements and body weights were recorded twice weekly. Calculations were made using [1-(T / C)] x 100. and >80% of control mice showed tumor growth inhibition (TGI) on the last day they remained on the study. All in vivo experiments were performed using the same methodology as Johnson and Johnson Ins Titional Animal Care and Use Committee and the Guide for Care and Use of Laborato This was done in accordance with the ry Animals.

[0179] In the H1975 model, JNJ-372 treatment resulted in 7% increased expression of IFN-γ compared to isotype control. 5% tumor growth inhibition (TGI) (Figure 31). However, JNJ-37 2. IgG2 Sigma was significantly less effective, with a TGI of only 30% (Figure 31). Similarly, JNJ-372 treatment significantly reduced tumor growth in the MET amplified SNU5 model. The TGI was 96%, whereas JNJ-372.IgG2 Sigma treatment was ineffective. (TGI was -17%) (Figure 32). Treatment had no effect on mouse body weight (Figure 32).

[0180] Example 6. Fc interactions induce NK cell-mediated ADCC, but not CDC Did not lead The ability of JNJ-372 to induce various Fc effector functions was examined. Using a europium release assay in the presence of PBMCs from donors JNJ-3 Antibody-mediated lysis of H1975 cells was measured by inducing ADCC by 72. Some donors showed approximately 60-70% ADCC activity, whereas others showed no significant difference. The NA did not have measurable ADCC activity (data not shown). To assess the contribution of engagement, we performed isotype-paired IgG1-specific ... H1975 cells were treated with control, JNJ-372, or JNJ-372.IgG2 Sigma. JNJ-372 induced dose-dependent ADCC, whereas the isotype control JNJ-3 72. No cell death was observed with IgG2 sigma treatment (data not shown). To determine the immune cell subtypes in PBMCs involved in 372-induced ADCC In addition, the NK cells were induced in the presence of PBMCs against isolated monocytes or NK cells from the same donor. Both PBMCs and NK cells were able to induce JNJ-372-dependent ADCC lysis. induced CC lysis but not isolated monocytes (Figure 33), indicating that NK cells express JNJ-3 This indicates that JNJ-372 or JNJ-72 is involved in the ADCC activity induced by the 372.IgG2 Sigma assayed against H1975 and H292 NSCLC cell lines No possible CDC activity was observed (data not shown), indicating that JNJ-372 inhibits these These results suggest that it does not induce CDC in NSCLC cell lines.

[0181] Example 7. Macrophages for JNJ-372-mediated tumor cell killing in vivo Phage effects To investigate the role of macrophages in vivo, we used anti-CSF1R antibody to 75 Depletion of tumor-associated macrophages in mice bearing xenograft tumors and J The efficacy of NJ-372 was measured. Treatment with anti-CSF1R antibody reduced T cell proliferation compared to untreated control. A significant decrease in AM was observed ( ** , p<0.002), and macrophages ranged from 11-15% The cells were then depleted to approximately 2% (Figure 34). Animals were treated with either JNJ-372.IgG2 Sigma or JNJ-372.IgG2 Sigma, but in both groups No weight loss was observed in the mice (data not shown). Treatment with 72 was superior to isotype controls in tumors treated with non-CSF1R antibodies ( ** * , p<0.0001) or JNJ-372.IgG2 Sigma treatment ( ** , p=0.00 4) showed significantly higher antitumor efficacy (Figure 35). Depletion of macrophages (anti-CS1R treatment) significantly reduced TGI from 72.8% to 38.5%. Reduce to ( *** , p<0.0001) (Figure 35), which indicates that JNJ-3 in vivo These results suggest that macrophages play an important role in mediating the antitumor efficacy of 72. There are.

[0182] These results demonstrate that macrophages are essential for antitumor efficacy in vivo. I testified.

[0183] Example 8. JNJ-372 Fc interaction with immune cells enhances antibody-dependent cytokine and and chemokine release (ADCR) The interaction of the Fc region of therapeutic antibodies with FcγR on immune cells mediates the expression of chemokines and cytokines. It is known that it induces the secretion of ADCR (Kinder et al., mAbs 7:494-504,2015). 71-plex MSD cytokine panel The isotype control, Chemochemical secretion upon treatment with JNJ-372 or JNJ-372.IgG2 Sigma In a treatment- and time-dependent manner, several secreted proteins were detected in the cells. Characteristic differences were observed in cytokines; 32 of 71 cytokines tested and 42 of 71 cytokines were reliably measurable at 4 and 72 hours, respectively. Cytokines with >1.5-fold differences between treatments were focused on. Further analysis showed that 13 and 14 species were detected at 4 hours (Figure 36) and 72 hours (Figure 37) after treatment, respectively. Seven cytokines were compared with isotype control or J in co-cultures of H1975+PBMCs. Upregulated when treated with JNJ-372 compared to NJ-372.IgG2 Sigma Many of the cytokines that were altered were chemotactic cytokines. They belong to the CC chemokine family (Fig. 6B-MIP1β, MCP-1, MCP -3, eotaxin, eotaxin-2), which act on innate immune cells, monocytes, and macrophages. It is known to function as a chemotactic factor for phages (Graves et al. ,Crit Rev Oral Biol Med 6:109-18,1995;Ug uccioni et al.,Eur J Immunol 25:64-8,199 5;Balkwill, Nat Rev Cancer 4:540-50,2004) .

[0184] We will further evaluate these cytokines and investigate the role of individual immune cells in their secretion. To investigate the function and changes of cytokines treated with JNJ-372, 23 cytokines were selected. on individual immune cells isolated from the same donor in the presence of PBMCs. In mice, mice were treated with isotype, JNJ-372, or JNJ-372.IgG2 sigma antibody. Heat map analysis was used to assess cytokine expression by individual immune cells. A distinctive change in pattern was revealed, with CC chemokines expressed across all immune cells. The most frequently upregulated family upon treatment with JNJ-372 was More focused analysis of cytokines with >1.5-fold differences in the presence of PBMCs. This resulted in the discovery of a method to detect NK cells that is specific to PBMCs, monocytes, and macrophages but not to NK cells. No specific pattern of upregulation was evident upon treatment with JNJ-372. For example, treatment with JNJ-372 resulted in increased expression of PBMCs or monocytes. The levels of MCP-1 (Figure 38) and MCP-3 (Figure 39) increased in a dose-dependent manner, whereas Neither isotype nor JNJ-372.IgG2 sigma was increased in the presence of NK cells. It is known to be secreted by monocytes and macrophages in response to stimuli activation. (Janson et al., J Immunol 147:4218-23, 1991;Arend et al.,Ann Rheum Dis 59 Suppl 1:i60-4, 2000) IL1-RA inhibited JNJ- Treatment with 372 increased the expression of NK cells in a dose-dependent manner, but not in NK cells (Figure 40). Furthermore, treatment with JNJ-372 significantly increased MIP1β levels in the presence of immune cells. A dose-dependent increase in IgG2 was observed, but not with the isotype control or JNJ-372.IgG2 signaling. In addition, the MIP family protein MIP1 was not observed in the mouse model (Figure 41). Both MIP1α and MIP1β inhibited JNJ-37 in coculture with M1 and M2 macrophages. 2 treatment, and MIP1β was upregulated in M2c macrophages. Figure 42 shows that fold changes of a larger magnitude were observed when the cells were cultured in the presence of M1 macrophages. FIG. 43 shows a dose response curve of MIP-1β levels in H1975 cells treated with M2 macrophages. Dose-response curve of MIP-1β levels in H1975 cells cultured in the presence of rophages FIG. 44 shows the MIP- FIG. 45 shows a dose response curve of 1α levels cultured in the presence of M2 macrophages. FIG. 1 shows a dose response curve for levels of MIP-1α in H1975 cells.

[0185] The effect of secreted chemokines on downregulation of EGFR / cMet To evaluate, isotype control was administered in the presence or absence of PBMCs for 4 or 72 hours. From H1975 cells treated with JNJ-372, or JNJ-372.IgG2 Sigma The conditioned medium was transferred to untreated H1975 cells to assess changes in the EGFR and cMet pathways. There was measurable downregulation of EGFR, pEGFR, and cMet protein levels. lysis was observed in the presence of conditioned medium at all time points (data not shown). This is because the secreted cytokines and chemokines downregulate EGFR / cMet. These results suggest that the effect of β-glucosamine on the regulation of β-glucosamine was not sufficient to induce enhanced regulation of β-glucosamine. This is because it requires direct antibody-mediated contact between tumor cells and immune cells. be.

[0186] Example 9. JNJ-372 Fc interactions with monocytes and macrophages in trogocytic leukocytes Induce ADCT Another important Fc effector function, trogocytosis (ADCT), is A method to measure the transfer of bound labeled antibodies to effector cells (macrophages) The results were evaluated using a flow cytometry-based assay. Red cells were co-cultured with M1 or M2c macrophages and AF488-labeled isotype Opsonized with AF48, JNJ-372, or JNJ-372.IgG2 Sigma The percentage of 8+ macrophages was evaluated. Labeled JNJ-372 was found to be predominantly M1 (Figure 46) and M1c (Fig. 47) macrophages in a dose-dependent manner, whereas the isotype control Neither JNJ-372.IgG2 sigma-conjugated antibody nor CD11b+ macrophages were detected. No visible NucLight Red+ macrophages were detected (data not shown). No phagocytosis was detected, indicating a lack of phagocytosis, because trogocytosis was not detected in this assay. These results suggest that this is the primary mechanism in

[0187] Visual confirmation of JNJ-372-induced trogocytosis in macrophages To investigate this, we performed time-lapse microscopy and identified macrophages with CD11b / CD14 antibodies. The cocktail was used to visualize nuclei using Hoechst staining, and the NucLight Red+ nuclei were H1975 target cells were identified by AF647-labeled isoforms. opsonized with type, JNJ-372, or JNJ-372.IgG2 Sigma antibodies; The cells were co-cultured with M1 or M2c macrophages and high-content confocal images were obtained. When co-cultured with JNJ-372-opsonized target cells, AF647+ puncta (J Distinct accumulation of NJ-372 was observed in M1 and M2 macrophages, but the labeled No accumulation was observed with either the selected isotype or JNJ-372.IgG2 Sigma treatment. As in the previous assays, minimal phagocytosis was observed in these assays, which is consistent with The primary mechanism of receptor downregulation by JNJ-372 is trogocytosis. Figure 48 shows that the high content confocal images at 11 minutes of a 44 minute incubation. Representative images from microscopy are shown. Figure 49 shows the results of the HA-10001 cells at 77 minutes of a 110 minute incubation. Representative images from content confocal microscopy are shown.

[0188] Next, we investigated the ability of monocytes to carry out trogocytosis. Monocytes co-cultured with JNJ-372 (AF647-labeled) opsonized target cells, This demonstrated the specific translocation of labeled JNJ-372 antibody to monocytes (data not shown). Finally, to simulate antibody interactions within the tumor microenvironment, we used M1 or M Co-culture of 2c macrophages and H1975 target cells with AF647-labeled isotype were treated with JNJ-372 or JNJ-372.IgG2 Sigma antibody. Below, the isotype control binds only to M1 and M2c macrophages, while JNJ-3 72. IgG2 sigma binds only to target cells, whereas JNJ-372 binds to both target cells and mammary Both antibodies bound to both phages (data not shown), thus confirming the binding specificity of each antibody. JNJ-372-mediated trogocytosis was confirmed by the expression of labeled JNJ-372. Similarly, in co-culture conditions, as measured by distinct transfer of the 2 antibodies to macrophages, This was easily observed with either the isotype or JNJ-372.IgG2 Sigma antibody. None observed.

[0189] Taken together, these findings suggest that JNJ-372 mediates the upregulation of Fcγ receptors on macrophages and monocytes. We demonstrate that it induces trogocytosis through interaction with receptors.

[0190] Consideration The experiments described herein demonstrate that the EGFR / cMet bispecific antibody, JNJ-372, We demonstrated that NK cells have multiple Fc-dependent mechanisms that contribute to their antitumor efficacy. In addition to inducing cell-mediated ADCC, JNJ-372 and Fc on immune cells Interaction with the γ-receptor mediates trogocytosis via the receptor tyrosine kinase EGFR and also mediates down-modulation of cMet and its phosphorylated forms. Fc function is promoted by monocytes and macrophages, which has antitumor effects in vivo. It is also needed for sex.

[0191] Fc interaction of JNJ-372 with immune cells results in anti-proliferative and apoptotic cell death in vitro. These results demonstrate that IL-1 is required for the vasopressin-dependent vasopressin (PS) upregulation and antitumor efficacy in vivo. In vitro, the maximum antiproliferative effect was observed after 48 hours, and ADCC occurred early (approximately 2 Given that the total tumor cell killing time is approximately 4 h (29), the contribution of ADCC to total tumor cell killing may be minimal. We hypothesized that CDC activity was not observed in the cell lines evaluated, but NSCLC cells The strain is known to express the complement inhibitory proteins, CD46, CD55, and CD59. (Varsano et al., Clin Exp Immunol 113: 173-82, 1998), which indicates that JNJ-372 induces CDC in the cells tested. Although the bispecific antibodies did not induce CDC activity in other cell lines or tumor types, Finally, it was suggested that JNJ-372 may be able to induce The induction of ADCP in tuna has already been reported (Moores et al., 2013). Ancer Res 76:3942-53, 2016) Under the conditions used in the confocal microscopy-based trogocytosis assay, ADCP These results suggest that JNJ-372 acts through multiple mechanisms of action. and that the contribution of each of these Fc effector functions differs between patients. It was suggested that he would get

[0192] It was also demonstrated that JNJ-372 induced ADCR. From the exploration of the functions of regulated cytokines, most of them are called chemokines. It appears to belong to the family of chemotactic cytokines, specifically CC chemokines (Graves et al., Crit Rev Oral Biol 6: 109-18,1995;Balkwill, Nat Rev Cancer 4:54 CC chemokines act on innate immune cells such as monocytes and macrophages. There are two major subfamilies that are known to function as chemotactic factors for monocytes. It is composed of chemotactic proteins (MCPs) and macrophage inflammatory proteins (MIPs). (Uguccioni et al., Eur J Immunol 25:64 -8,1995;Loetscher et al.,FASEB J 8:1055- 60, 1994). MCP family members, MCP-1 (CCL2) and MCP-3 (CCL7) has been shown to increase the recruitment of inflammatory monocytes and CD8+ T lymphocytes. (Uguccioni et al., Eur J Immunol 25:64- 8,1995;Loetscher et al.,FASEB J 8:1055-6 0,1994;Jia et al.,J Immunol 180:6846-53, MCP-1 and MIP1β (CCL4) are also involved in the tumor microenvironment of NSCLC. It has also been reported to induce recruitment of monocytes and macrophages into the TME (Ugu ccioni et al.,Eur J Immunol 25:64-8,1995 ;Arenberg et al.,Cancer Immunol Immunoth er 49:63-70,2000).

[0193] These cytokines can attract and activate immune cells to the TME. However, the requirement for antibody-mediated cell-cell contact and induction of trogocytosis are not known. 372 Fc interactions down-modulate EGFR and cMet signaling The mechanism of action is via monocyte- or macrophage-mediated trogocytosis Several recent reports have suggested that trogocytosis leads to the proliferation of macrophages. Similar transfer of the Her2 receptor to immune cells such as lymphocytes and neutrophils may facilitate the development of therapeutic antibody options. It has been shown that sonification of tumor cells leads to death (Velmurugan et al., Mol Cancer Ther 15:1879-89,2016;Matlung et al., Cell Rep 23:3946-59, 2018). , trogocytosis was thought to be a mechanism of resistance to antibodies such as rituximab. However, it was suggested that it may also have an Fc effector function mediating antitumor effects. (Taylor and Lindofer,Blood 125:762-6,201 5; Pham et al., PLoS One 6:e14498, 2011).

[0194] In conclusion, JNJ-372 possesses several Fc-dependent and -dependent mechanisms that contribute to its antitumor activity. It has been demonstrated that the in vitro In vitro and in vivo models demonstrate the interaction of JNJ-372 with FcγRs on monocytes and macrophages. The interaction is necessary for EGFR / Met down-modulation and anti-tumor efficacy, This suggests that the levels of these immune cells may predict JNJ-372 efficacy in a clinical setting. This suggests that it is possible.

Claims

1. 1. A pharmaceutical composition for use in a method of treating a subject having an EGFR, c-Met, or EGFR and c-Met expressing cancer, comprising: The pharmaceutical composition comprises an isolated bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody; The method comprises administering to the subject a therapeutically effective amount of the isolated bispecific anti-EGFR / c-Met antibody in combination with an agent that enhances macrophage activity in the subject.

2. 1. A pharmaceutical composition for use in a method of treating a subject having an EGFR, c-Met, or EGFR and c-Met expressing cancer, comprising: The pharmaceutical composition comprises an agent that enhances macrophage activity in the subject, The method comprises administering to the subject a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody in combination with an agent that enhances macrophage activity.

3. 1. A pharmaceutical composition for use in a method of treating a subject having an EGFR, c-Met, or EGFR and c-Met expressing cancer, comprising: The pharmaceutical composition comprises an isolated bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody and an agent that enhances macrophage activity in the subject; The method comprises administering to the subject a therapeutically effective amount of the isolated bispecific anti-EGFR / c-Met antibody in combination with an agent that enhances the macrophage activity.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the bispecific anti-EGFR / c-Met antibody and the agent that enhances macrophage activity in the subject are administered simultaneously as single agents or sequentially as single agents in any order, by the same or different routes of administration.

5. The bispecific anti-EGFR / c-Met antibody is a) a first domain that binds to EGFR, the first domain comprising a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6; b) a second domain that binds to c-Met, the second domain comprising an HCDR1 of SEQ ID NO:7, an HCDR2 of SEQ ID NO:8, an HCDR3 of SEQ ID NO:9, an LCDR1 of SEQ ID NO:10, an LCDR2 of SEQ ID NO:11, and an LCDR3 of SEQ ID NO:12; The pharmaceutical composition according to any one of claims 1 to 4, comprising:

6. a) the first domain that binds to EGFR comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14; b) the second domain that binds c-Met comprises a VH of SEQ ID NO: 15 and a VL of SEQ ID NO: 16; The pharmaceutical composition according to claim 5.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the bispecific anti-EGFR / c-Met antibody is of the IgG1 isotype.

8. 8. The pharmaceutical composition of any one of claims 1 to 7, wherein the bispecific anti-EGFR / c-Met antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19, and a second light chain (LC2) of SEQ ID NO:

20.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the agent that enhances macrophage activity is GM-CSF, an anti-CD47 antibody, an HDAC2 inhibitor, a PD-(L)1 axis inhibitor, or a CD11b agonist.

10. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein the EGFR or c-Met expressing cancer is associated with wild-type EGFR, EGFR activating mutations, EGFR gene amplification, elevated levels of circulating HGF, wild-type c-Met, c-Met activating mutations, c-Met gene amplification, or mutant KRAS.

11. The EGFR activating mutation is a substitution of L718Q, G719A, G719X (X is any amino acid), L861X (X is any amino acid), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, C797S, L858P, or T790M, a deletion of E746 to A750, a deletion of R748 to P753, an insertion of Ala (A) between M766 and A767, an insertion of Ser, Val, and Ala (SVA) between S768 and V769, an insertion of Asn and S between P772 and H773, or an insertion of β-amino acid between P772 and H773.

11. The pharmaceutical composition of claim 10, comprising an insertion of er(NS), an insertion of one or more amino acids between D761 and E762, A763 and Y764, Y764 and Y765, M766 and A767, A767 and V768, S768 and V769, V769 and D770, D770 and N771, N771 and P772, P772 and H773, H773 and V774, V774 and C775, one or more deletions in EGFR exon 20, or one or more insertions in EGFR exon 20, or any combination thereof.

12. 11. The pharmaceutical composition of claim 10, wherein the mutant KRAS comprises a G12V, G12C, G12A, or G12D substitution, or any combination thereof.

13. The pharmaceutical composition of any one of claims 1 to 12, wherein the subject has a newly diagnosed EGFR, c-Met, or EGFR and c-Met expressing cancer.

14. The pharmaceutical composition of any one of claims 1 to 12, wherein the subject is resistant or has acquired resistance to treatment with a previous anti-cancer therapy.

15. 15. The pharmaceutical composition of claim 14, wherein the previous anti-cancer therapy is a chemotherapy, a targeted anti-cancer therapy, or a kinase inhibitor.

16. 16. The pharmaceutical composition of claim 15, wherein the kinase inhibitor is an inhibitor of EGFR, c-Met, HER2, HER3, HER4, VEGFR, or AXL.

17. 17. The pharmaceutical composition of claim 16, wherein the kinase inhibitor is erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, cliotinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib, or sunitinib.

18. 18. The pharmaceutical composition of any one of claims 1 to 17, wherein the EGFR, c-Met, or EGFR and c-Met expressing cancer is epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, small cell lung cancer, colorectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer, pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, cervical cancer, splenic cancer, testicular cancer, gastric cancer, thymic cancer, colon cancer, thyroid cancer, liver cancer, hepatocellular carcinoma (HCC), or sporadic or hereditary papillary renal cell carcinoma (PRCC).

19. The pharmaceutical composition of any one of claims 1 to 18, wherein the method further comprises administering to the subject one or more anti-cancer therapies.

20. 20. The pharmaceutical composition of claim 19, wherein the one or more anti-cancer therapies comprise a chemotherapy, a targeted anti-cancer therapy, or a kinase inhibitor.

21. 21. The pharmaceutical composition of claim 20, wherein the kinase inhibitor is an inhibitor of EGFR, c-Met, HER2, HER3, HER4, VEGFR, or AXL.

22. 22. The pharmaceutical composition of claim 21, wherein the kinase inhibitor is erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, cliotinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib, or sunitinib.